var title_f17_57_18320="Elevated PD pressure manometry";
var content_f17_57_18320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Sphincter of Oddi manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of elevated basal sphincter of Oddi (SO) pressure in the pancreatic segment (PD) of the SO.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Walter J Hogan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18320=[""].join("\n");
var outline_f17_57_18320=null;
var title_f17_57_18321="Contents: Primary care dermatology";
var content_f17_57_18321=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care dermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care dermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Benign and malignant melanocytic lesions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44056\">",
"           Acquired melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22009\">",
"           Pathologic characteristics of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1206\">",
"           Pathologic evaluation of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites/Stings/Infestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39286\">",
"           Bedbugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/34/43556\">",
"           Chigger bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43016\">",
"           Jellyfish stings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25849\">",
"           Pediculosis capitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24339\">",
"           Pediculosis corporis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1511\">",
"           Pediculosis pubis and pediculosis ciliaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/2/28712\">",
"           Scabies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous lymphomas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/47/25337\">",
"           Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4618\">",
"           Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35400\">",
"           Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15464\">",
"           Primary cutaneous follicle center lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26391\">",
"           Primary cutaneous large B cell lymphoma, leg type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26776\">",
"           Primary cutaneous marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4713\">",
"           Staging and prognosis of mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36410\">",
"           Treatment of advanced stage (IIB to IV) mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17017\">",
"           Treatment of early stage (IA to IIA) mycosis fungoides",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40660\">",
"           Intralesional injection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of pigmentation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/17/43287\">",
"           Benign pigmented skin lesions other than melanocytic nevi (moles)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of skin adnexal structures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/35/44599\">",
"           Hormonal therapy for women with acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/54/33639\">",
"           Light-based, adjunctive, and other therapies for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22184\">",
"           Oral isotretinoin therapy for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/7/6265\">",
"           Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1257\">",
"           Primary focal hyperhidrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36343\">",
"           Pseudofolliculitis barbae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24266\">",
"           Treatment of hidradenitis suppurativa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug eruptions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35834\">",
"           Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General diagnosis and treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/28/37318\">",
"           Approach to the patient with a scalp eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29831\">",
"           Approach to the patient with macular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28423\">",
"           Approach to the patient with pustular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27752\">",
"           General principles of dermatologic therapy and topical corticosteroid use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/34/553\">",
"           Overview of benign lesions of the skin",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genital dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5336\">",
"           Dermatitis of the vulva",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36952\">",
"           Vulvar lichen planus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hair and nails",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10856\">",
"           Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/46/1768\">",
"           Clinical manifestations and diagnosis of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4330\">",
"           Management of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13846\">",
"           Nonscarring hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/61/37846\">",
"           Paronychia and ingrown toenails",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37014\">",
"           Removal of unwanted hair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23336\">",
"           Treatment of androgenetic alopecia in men",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26249\">",
"           Cutaneous warts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/43/11959\">",
"           Erythrasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29098\">",
"           Fever and rash in the immunocompetent patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6842\">",
"           Molluscum contagiosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5258\">",
"           Onychomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43142\">",
"           Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31687\">",
"           Soft tissue infections following water exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3320\">",
"           Tinea versicolor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/18/21802\">",
"           Cutaneous manifestations of internal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29657\">",
"           Dermatoses of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13130\">",
"           Erythema nodosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31381\">",
"           Grover's disease (transient and persistent acantholytic dermatosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30614\">",
"           Hypersensitivity vasculitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1847\">",
"           Keloids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4774\">",
"           Management of intergluteal pilonidal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7285\">",
"           Metabolic and inherited diseases affecting the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31082\">",
"           Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/43/30393\">",
"           Neutrophilic dermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/11/25786\">",
"           Oral lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-melanoma skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6712\">",
"           Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7351\">",
"           Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/39/14970\">",
"           Epidemiology and clinical features of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/56/25482\">",
"           Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/5/44121\">",
"           Nevoid basal cell carcinoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/31/3577\">",
"           Staging and treatment of Merkel cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14293\">",
"           Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13690\">",
"           Treatment and prognosis of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31209\">",
"           Treatment and prognosis of cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30968\">",
"           Treatment of actinic keratosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Papulosquamous disorders and dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42631\">",
"           Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27625\">",
"           Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9656\">",
"           Lichen planus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/4/41030\">",
"           Management of psoriasis in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44457\">",
"           Management of severe refractory atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3721\">",
"           Overview of dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/18999\">",
"           Pityriasis rosea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20168\">",
"           Poison ivy (Toxicodendron) dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26551\">",
"           Role of allergy in atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10842\">",
"           Treatment of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40042\">",
"           Treatment of psoriasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pediatric dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/13/22745\">",
"           Benign skin and scalp lesions in the newborn and young infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26104\">",
"           Contact dermatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44665\">",
"           Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5495\">",
"           Evaluation and diagnosis of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40985\">",
"           Localized scleroderma in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25546\">",
"           Management of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/33/37401\">",
"           Overview of diaper dermatitis in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6840\">",
"           Skin nodules in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4727\">",
"           Sturge-Weber syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/21/30038\">",
"           Vascular lesions in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15864\">",
"           Vesiculobullous and pustular lesions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Photodermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27142\">",
"           Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/63/18426\">",
"           Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/62/20455\">",
"           Polymorphous light eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/27/30136\">",
"           Sunburn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyrias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41687\">",
"           Hereditary coproporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30421\">",
"           Porphyria cutanea tarda and hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28458\">",
"           Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/51/825\">",
"           Variegate porphyria",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44087\">",
"           Classification of scleroderma disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43095\">",
"           Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31079\">",
"           Diagnosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/22/11626\">",
"           Initial treatment of dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39433\">",
"           Juvenile systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38566\">",
"           Malignancy in dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/33/36378\">",
"           Mucocutaneous manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29224\">",
"           Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13642\">",
"           Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/11/37045\">",
"           Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/65\">",
"           Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13065\">",
"           Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30010\">",
"           Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24666\">",
"           Physical urticarias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-775EAF1A43-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_57_18321=[""].join("\n");
var outline_f17_57_18321=null;
var title_f17_57_18322="Glucagon injection PI";
var content_f17_57_18322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Glucagon shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To give a glucagon shot:",
"    <br>",
"     <ol>",
"      <li>",
"       Hold the syringe at a 90 degree angle to the lower belly or upper leg (as shown in the photograph).",
"      </li>",
"      <li>",
"       Quickly stick the needle in the skin and push the plunger down all the way.",
"      </li>",
"      <li>",
"       Remove the needle from the skin.",
"      </li>",
"      <li>",
"       Press down lightly on the skin where the shot was given.",
"      </li>",
"      <li>",
"       Turn the person onto his or her side in case he or she vomits.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18322=[""].join("\n");
var outline_f17_57_18322=null;
var title_f17_57_18323="Hydroxypropyl cellulose: Patient drug information";
var content_f17_57_18323=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroxypropyl cellulose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29714?source=see_link\">",
"     see \"Hydroxypropyl cellulose: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lacrisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lacrisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroxypropyl cellulose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11778 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18323=[""].join("\n");
var outline_f17_57_18323=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180920\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016750\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016749\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016754\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016755\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016757\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016752\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016753\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016758\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016759\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29714?source=related_link\">",
"      Hydroxypropyl cellulose: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18324="Anorexia nervosa heart and lung changes";
var content_f17_57_18324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiographic changes associated with anorexia nervosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative posterior-anterior \"locating scout\" and thin slice computed tomographic (CT) images from a control patient with a BMI of 19 kg/m2 (A and B), and from an anorexic patient with a BMI of 12 kg/m2 (C and D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coxson, HO, et al. Am J Respir Crit Care Med 2004; 170:748.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18324=[""].join("\n");
var outline_f17_57_18324=null;
var title_f17_57_18325="Pericyazine: Patient drug information";
var content_f17_57_18325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pericyazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11462?source=see_link\">",
"     see \"Pericyazine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1963008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neuleptil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change the electrical activity in your heart. This change could cause fast heartbeats. This drug does not mix well with many drugs. Check all drugs with your doctor before starting this drug. If you have a history of fast heartbeats, tell your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat problems with how one acts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to periciazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703418",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, brain problem, a fast heartbeat, liver disease, or low blood cell count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not spill the liquid on the skin. This may irritate the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need an ECG before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills. Mix with distilled water, orange juice, or grape juice before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11513 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18325=[""].join("\n");
var outline_f17_57_18325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963008\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022708\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022710\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022709\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022714\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022715\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022717\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022712\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022713\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022718\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022719\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11462?source=related_link\">",
"      Pericyazine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18326="Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information";
var content_f17_57_18326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/34/22049?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/25/3478?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pediarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/25/3478?source=see_link\">",
"      see \"Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     Children 6 weeks to &lt;7 years: I.M.: 0.5 mL/dose; administer as a 3-dose series at 2-, 4-, and 6 months of age  in 6- to 8-week intervals (preferably 8-week intervals). Vaccination usually begins at 2 months, but may be started as early as 6 weeks of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Pediarix&reg; is approved for the first 3 doses of polio vaccine. Per the ACIP, polio vaccine is given at 2, 4 and 6 months of age and should not be administered more frequently than 4 weeks apart. Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Use in children previously vaccinated with one or more component, and who are also scheduled to receive all vaccine components:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hepatitis B vaccine:",
"     </i>",
"     Infants previously vaccinated with 1 or 2 doses of another hepatitis B vaccine may use Pediarix&reg; to complete the 3-dose series. Not for use as birth dose of hepatitis B vaccine. Infants born to HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive women should begin dosing with DTaP-HepB-IPV by age 6-8 weeks after receiving the single antigen hepatitis B vaccine at birth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Diphtheria and tetanus toxoids, and acellular pertussis vaccine (DTaP):",
"     </i>",
"     Infants previously vaccinated with 1 or 2 doses of Infanrix&reg; may use Pediarix&reg; to complete the first 3 doses of the series; use of Pediarix&reg; to complete DTaP vaccination started with products other than Infanrix&reg; is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inactivated polio vaccine (IPV):",
"     </i>",
"     Infants previously vaccinated with 1 or 2 doses of IPV may use Pediarix&reg; to complete the first 3 doses of the series.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediarix&reg;: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutin 25 mcg, pertactin 8 mcg, HBsAg 10 mcg, type 1 poliovirus 40 D antigen units, type 2 poliovirus 8 D antigen units and type 3 poliovirus 32 D antigen units] per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate (trace amounts), polymyxin B (trace amounts), polysorbate 80, and yeast protein &le;5%; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. use only; do not administer I.V., SubQ, or intradermally. Shake well prior to use; do not use unless a homogeneous, turbid, white suspension forms. Administer in the anterolateral aspects of the thigh or the deltoid muscle of the upper arm. Do not inject in the gluteal area (suboptimal hepatitis B immune response) or where there may be a major nerve trunk. Do not administer additional vaccines or immunoglobulins at the same site, or using the same syringe.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F161326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other vaccines or injections.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination vaccine for the active immunization against diphtheria, tetanus, pertussis, hepatitis B virus (all known subtypes), and poliomyelitis (caused by poliovirus types 1, 2, and 3)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends Pediarix&reg; for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     - Primary vaccination for DTaP, Hep B, and IPV in children at 2, 4, and 6 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     - To complete the primary vaccination series in children who have received DTaP (Infanrix&reg;) and who are scheduled to receive the other components of the vaccine. Whenever feasible, the same manufacturer should be used to provide the pertussis component; however, vaccination should not be deferred if a specific brand is not known or is not available. HepB and IPV from different manufacturers are interchangeable.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adverse events reported within 4 days of vaccination at 2-, 4-, and 6 months of age in patients given Pediarix&reg; concomitantly with Hib conjugate vaccine and PCV7 vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Irritability/fussiness (61% to 65%; grade 3: 3% to 4%), drowsiness (41% to 57%), fever &ge;100.4&deg;F (28% to 39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Loss of appetite (26% to 31%; grade 3: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Redness (25% to 40%; &gt;20 mm: 1% to 3%), pain (31% to 36%; grade 3: 2% to 3%), swelling (17% to 29%; &gt;20 mm: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%: Central nervous system: Fever &gt;103.1&deg;F (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional and postmarketing events: Anaphylactic/anaphylactoid reaction, angioedema, anorexia, apnea, arthus-type hypersensitivity  reactions, brachial neuritis, bulging fontanelle, consciousness depressed, cough, cranial mononeuropathy, crying, cyanosis, demyelinating disease, diarrhea, dyspnea, encephalitis, erythema, fatigue, febrile convulsion, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, hypotonia, hypotonic-hyporesposnive episode, injection site reactions (cellulitis, induration, itching, nodule, warmth, vesicles), insomnia, lethargy, limb pain, limb swelling, liver function test abnormalities, nervousness, pallor, peripheral mononeuropathy, petechiae, rash, restlessness, screaming, seizure, SIDS, somnolence, upper respiratory tract infection, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphtheria and tetanus toxoids, pertussis, hepatitis B, poliovirus vaccine, or any component of the vaccine; encephalopathy occurring within 7 days of a previous pertussis vaccine not (not attributable to another identifiable cause); progressive neurologic disorders (including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Apnea: Apnea has been reported following I.M. vaccine administration in premature infants; consider risk versus benefit in infants born prematurely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reactions from previous pertussis vaccine: Carefully consider use in patients with history of any of the following effects from previous administration of a pertussis-containing vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; shock or collapse (hypotonic-hyporesponsive episode [HHE]) occurring within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic disorders: Use with caution in patients with history of seizure disorder, progressive neurologic disease, or conditions predisposing to seizures; ACIP and AAP guidelines recommend deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever. The use of Pediarix&reg; combination vaccine is associated with higher rates of fever in comparison to the separate administration of individual components.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concurrent drug therapy issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Infants born of HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive mothers should receive monovalent hepatitis B vaccine and hepatitis B immune globulin; infants born of HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-unknown mothers should receive monovalent hepatitis B vaccine; use of combination product in these patients to complete the hepatitis B vaccination series is limited but is considered acceptable by the ACIP.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Product may contain aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Product may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polymyxin B: Product may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Yeast protein: Product may contain yeast protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Booster dose: Not approved for the fourth dose of the IPV series or the fourth and fifth doses of the DTaP series.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; not indicated for women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F161302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10142624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Infanrix Penta (AU, CZ, GR, IT);",
"     </li>",
"     <li>",
"      Infanrix-IPV + HIB (BB, BM, BS, BZ, DE, GY, HK, ID, JM, MY, NL, PE, PH, PR, SG, SR, TT, TW);",
"     </li>",
"     <li>",
"      Infanrix-IPV-HIB (IL, NZ, VE);",
"     </li>",
"     <li>",
"      Infanrix-IPV/Hib (TH);",
"     </li>",
"     <li>",
"      Infanrix-Polio + Hib (SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, hepatitis B and poliovirus (types 1, 2 and 3) by inducing production of specific antibodies and antitoxins.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Immune response observed to all components 1 month following the 3-dose series",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), and Poliovirus Vaccine Combined, (PEDIARIX) for Use in Infants,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2003, 52(10):203-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(30):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/19661857/pubmed\" id=\"19661857\" target=\"_blank\">",
"        19661857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/57/18326/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9426 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18326=[""].join("\n");
var outline_f17_57_18326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161320\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161315\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804845\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804846\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161293\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161282\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161295\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161326\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161294\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161318\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161298\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161285\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299221\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161288\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161302\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10142624\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992798\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161284\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161297\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/34/22049?source=related_link\">",
"      Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/25/3478?source=related_link\">",
"      Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18327="Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging";
var content_f17_57_18327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     M Fatih Okcu, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     John Hicks, MD, DDS, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Marc Horowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18327/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/57/18327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas are rare, malignant tumors that can arise from mesenchymal tissue at any body site. The histopathologic spectrum of sarcomas is broad, presumably because the embryonic mesenchymal cells from which they originate have the capacity to mature into striated skeletal and smooth muscle, adipose and fibrous tissue, bone, and cartilage.",
"   </p>",
"   <p>",
"    Rhabdomyosarcomas (RMS) are thought to originate from immature cells that are destined to form striated skeletal muscle; however, these tumors can arise in locations where skeletal muscle is not typically found (eg, the urinary bladder). Undifferentiated sarcomas (UDS) derive from mesenchyme that cannot be ascribed to a specific tissue lineage.",
"   </p>",
"   <p>",
"    The treatment of RMS has evolved considerably over the past several decades. Cure rates have risen, largely due to the increasingly intensive, multimodality therapeutic protocols that have been developed by large international cooperative groups, such as the Intergroup Rhabdomyosarcoma Study Group (IRSG). The IRSG has now become the Soft Tissue Sarcoma Committee of the Children's Oncology Group, and the designation IRS is no longer used for cooperative group trials.",
"   </p>",
"   <p>",
"    This topic review will cover the clinical presentation, diagnostic evaluation, staging, and risk stratification for purposes of treatment selection among patients with RMS and UDS. The epidemiology, pathology, molecular pathogenesis, and specific issues related to treatment are discussed elsewhere, as are primary tumors of bone, and other soft tissue neoplasms arising in children as well as adults are discussed elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting signs and symptoms of RMS are variable, and are influenced by the site of origin, the age of the patient, and the presence or absence of distant metastases. In general, the primary lesion has the appearance of a nontender mass, occasionally with overlying skin erythema. A history of antecedent trauma is uncommon, and fever is only rarely present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Presentation by anatomic site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any body part can be affected by RMS. However, the most common primary sites are the head and neck region (35 to 40 percent), the genitourinary (GU) tract (25 percent), and the extremities (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The impact of the primary site location on prognosis is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef76178 \" href=\"UTD.htm?17/3/17468\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck primary RMS can arise in the orbit (25 percent), parameningeal sites (middle ear, nasal cavity, paranasal sinuses, nasopharynx, and infratemporal fossa: 50 percent), or other locations (including the scalp, parotid gland, oral cavity, pharynx, thyroid and parathyroid glands, and neck: 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/5\">",
"     5",
"    </a>",
"    ]. RMS involving the head or neck is most commonly of the embryonal subtype and rarely involves regional lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link&amp;anchor=H10#H10\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Embryonal RMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Orbital tumors produce proptosis and occasionally, ophthalmoplegia, while parameningeal lesions can cause nasal, aural, or sinus obstruction with or without a mucopurulent or sanguineous discharge. Head and neck RMS arising from sites other than these typically present as a localized painless, enlarging mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H19#H19\">",
"     \"Head and neck sarcomas\", section on 'Rhabdomyosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Genitourinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overwhelming majority of GU tract RMS are of the embryonal type, and many are of the botryoid variant. &nbsp;They can arise from the bladder, prostate, or the male or female genital tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link&amp;anchor=H10#H10\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Embryonal RMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bladder tumors may be associated with hematuria and urinary obstruction, while prostatic primaries typically present as large pelvic masses causing urinary frequency or constipation from extrinsic compression of the bladder or intestinal tract.",
"   </p>",
"   <p>",
"    Vaginal tumors tend to develop in very young girls and are accompanied by a mucosanguineous discharge; a polypoid mass may protrude from the vagina. Cervical and uterine tumors are more common in older girls. Paratesticular tumors can produce scrotal or inguinal enlargement in prepubertal or postpubertal boys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Extremities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremity tumors tend to arise in adolescents, and the typical presentation is that of a painful mass or swelling, with or without erythema of the overlying skin. Between 50 and 75 percent of extremity RMS are of the alveolar type, and they are more likely to spread to regional lymph nodes and along fascial planes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common sites of primary disease include the trunk, chest wall, perineal-perianal region, and biliary tract. Primary RMS of the liver, brain, trachea, heart, breast, and ovary have all been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of locoregional lymph node involvement depends upon the primary disease site. Lymphatic spread is unusual with head and neck primaries, particularly in children under the age of 10. In contrast, nodal involvement is present in up to one-half of patients with extremity lesions and in over one-half of boys over the age of 10 who present with paratesticular primary sites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study from the Intergroup Rhabdomyosarcoma Study (IRS)-IV suggests that the presence of regional nodal metastases negatively impacts the prognosis of patients with alveolar tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/11\">",
"     11",
"    </a>",
"    ] suggesting that more aggressive therapy might be warranted in this subgroup of patients. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prognostic stratification scheme for risk-adapted therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 25 percent of patients have overt distant metastatic disease at diagnosis, and over one-half of these have only a single site of metastatic involvement, typically lung [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Other sites of distant metastatic involvement include bone marrow (approximately 30 percent), bone (30",
"    <span class=\"nowrap\">",
"     percent);omentum/ascites",
"    </span>",
"    (16 percent), and pleura (13 percent);visceral involvement and brain metastases are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the small number of patients who have clinically overt metastases at diagnosis, it is presumed that the majority of patients who present with apparently localized disease have subclinical metastatic disease. This is based on the observation that before the routine use of systemic chemotherapy as a component of primary multimodal therapy, a substantial number of patients developed metastases and died of their disease despite achieving local tumor control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL DIAGNOSTIC AND STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entire team of specialists (including the surgeon and radiotherapist) who will be involved in the care of the child with RMS must have the opportunity to evaluate the patient at the time of initial diagnosis. It is particularly important that the anatomic boundaries of the tumor (which determine the tumor stage, risk stratification, and treatment) be documented",
"    <strong>",
"     prior",
"    </strong>",
"    to starting therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, the initial diagnostic biopsy should be performed at a facility with expertise in the evaluation of the child with a soft tissue or bone sarcoma to ensure that the tissue is processed properly, and to allow for the special studies that are essential for accurate diagnosis and histologic classification (",
"    <a class=\"graphic graphic_table graphicRef62670 \" href=\"UTD.htm?41/10/42155\">",
"     table 2",
"    </a>",
"    ). Review of the diagnostic material by a pediatric pathologist with special expertise in this area should be strongly considered because of the profound implications of a precise diagnosis on treatment and outcome.",
"   </p>",
"   <p>",
"    The classification of a tumor as RMS requires the identification of features of skeletal muscle lineage. Typically, this involves light microscopic identification of rhabdomyoblasts or cross-striations that are characteristic of skeletal muscle. For cases that lack these features, immunohistochemical staining (IHC) or electron microscopy may provide evidence supporting myogenic differentiation. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link&amp;anchor=H5#H5\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Histology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of recommended initial staging studies is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73916 \" href=\"UTD.htm?1/31/1531\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial radiologic evaluation should include plain radiographs of the affected area, as well as computed tomography (CT) scan or magnetic resonance imaging (MRI) of the primary site and surrounding structures. Children under the age of 10 who have a primary paratesticular tumor should undergo abdominal CT (thin cut 5 mm sections) to evaluate retroperitoneal nodal involvement.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is increasingly considered the imaging method of choice for certain primary locations, such as head and neck, extremity, parameningeal, and pelvic tumors, because of its multiplanar capacity, ability to attenuate bone artifact, and superior soft tissue contrast. Ultrasonography may provide additional information in patients with pelvic tumors (particularly involving the bladder), because the characteristic water density of urine helps in tumor localization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Metastatic workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a minimum, the metastatic workup should include bilateral bone marrow aspiration and biopsy, chest CT and a radionuclide bone scan. Sites that appear abnormal on bone scan should be investigated further with plain radiographs and, if findings are equivocal, MRI.",
"   </p>",
"   <p>",
"    Routine brain imaging appears unwarranted in asymptomatic patients who have tumors arising outside of the head and neck region [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of PET scanning in the initial staging evaluation (particularly to identify metastases that are missed by conventional radiographic imaging methods) and in monitoring the response to therapy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Prospective study of the contribution of PET scanning to risk stratification, treatment selection, and prognosis is needed. In the opinion of the authors, this test should only be used in a protocol setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial baseline laboratory studies should include a complete blood count with differential, serum electrolytes, blood urea nitrogen, liver function tests, and serum levels of creatinine, phosphorus, magnesium, uric acid, and calcium. Although uncommon, hypercalcemia can occur in patients with or without bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/22\">",
"     22",
"    </a>",
"    ]. Baseline coagulation studies should be obtained, although disseminated intravascular coagulation as a presenting manifestation of RMS is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H23#H23\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although unnecessary in most patients, pretreatment lumbar puncture is recommended in those with a parameningeal primary RMS (including middle ear, nasal cavity, paranasal sinuses, nasopharynx, and infratemporal fossa sites) or evidence of meningeal invasion by imaging studies. Although uncommon, leptomeningeal dissemination can occur in such patients; if present, craniospinal irradiation must be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719050272\">",
"    <span class=\"h3\">",
"     Lymph node assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of enlarged lymph nodes is necessary to confirm local metastatic disease. If this is not feasible or not performed for whatever reason, local control with radiotherapy should include those nodes that are clinically presumed to be involved.",
"   </p>",
"   <p>",
"    In the absence of pathologically enlarged nodes, sentinel node biopsy is indicated for all extremity tumors. Furthermore, all boys 10 years of age or older who have a paratesticular RMS should undergo routine ipsilateral nerve-sparing retroperitoneal lymph node dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=see_link&amp;anchor=H4#H4\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     STAGING AND PROGNOSTIC STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to most other solid tumors, prognosis and treatment recommendations are based upon several factors in addition to disease extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical grouping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used surgicopathologic staging schema is the clinical grouping (CG) system developed by the IRSG in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. Based upon data derived from IRSG I and II on degree of tumor spread at diagnosis and the amount of disease remaining after initial surgery, this system recognizes four disease categories (stage I through IV), with distinctly different prognoses (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     TNM system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the CG system is clinically useful for assigning treatment, it does not take into account other important prognostic factors, such as tumor size and primary site, extent of disease, nodal involvement, histology, and patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. To address some of these concerns, a pretreatment tumor-node-metastasis (TNM) staging system was developed and incorporated into the fourth IRSG Protocol (IRS-IV) (",
"    <a class=\"graphic graphic_table graphicRef62717 \" href=\"UTD.htm?7/13/7389\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This modified TNM system assigns one of four disease stages (from 1 through 4, Arabic numerals) based upon the site and size of the primary lesion, degree of local extension, regional nodal involvement, and presence or absence of metastatic disease. Favorable disease sites include the orbit and eyelid, other nonparameningeal head and neck locations, and nonbladder, nonprostate genitourinary tumors (eg, paratesticular tumors), while unfavorable sites include the extremities, bladder and prostate, cranial parameningeal sites, the trunk, and retroperitoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognostic stratification scheme for risk-adapted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM and CG staging systems complement each other, and both are used in modern classification schemes to assess prognosis and select treatment for individual patients with RMS. The prognostic stratification schema that was adopted by the IRSG for its current study protocol combines information from the CG and TNM staging systems as well as histologic variant to stratify patients into three distinct prognostic groups with very good, good, or poor prognosis (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/28\">",
"     28",
"    </a>",
"    ]. These prognostic categories are then used as the basis for treatment selection, a process referred to as risk-adapted therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modifications to these risk-adapted therapy assignments have been proposed (but not yet adopted) based upon analysis of data from IRSG protocols III and IV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18327/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8829029\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presenting signs and symptoms of rhabdomyosarcoma (RMS) are variable, and influenced by site of origin, age of the patient, and the presence or absence of distant metastases. In general, the primary lesion has the appearance of a nontender mass, occasionally with overlying skin erythema. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Presentation by anatomic site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accurate staging requires identification of the primary tumor site, size, extent of disease (nodal, metastases) and histologist subtype. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial diagnostic and staging evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphatic spread is unusual with head and neck primaries, but is present in up to one-half of patients with extremity lesions and in over one-half of boys over the age of 10 who present with paratesticular primary sites. Clinically and radiographically enlarged nodes warrant biopsy. In the absence of enlarged nodes, sentinel lymph node biopsy is indicated for all extremity tumors, and all boys 10 years of age or older who have a paratesticular RMS should undergo routine ipsilateral nerve-sparing retroperitoneal lymph node dissection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Regional nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fewer than 25 percent of patients have overt distant metastatic disease at diagnosis, and over one-half of these have only a single site of metastatic involvement, typically lung. Subclinical metastatic disease is presumed to be present in the majority of patients who present with apparently localized disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Distant metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial diagnostic biopsy should be performed at a facility with expertise in the evaluation of the child with a soft tissue or bone sarcoma to ensure that the tissue is processed properly and to allow for the special studies that are essential for accurate diagnosis and histologic classification. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A summary of recommended initial staging studies is shown in the table (",
"      <a class=\"graphic graphic_table graphicRef73916 \" href=\"UTD.htm?1/31/1531\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Staging evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to most other solid tumors, prognosis and treatment recommendations are based upon several factors in addition to disease extent. The prognostic stratification schema adopted for RMS clinical protocols combines information from the clinical group (CG) and TNM staging systems as well as histologic variant to stratify patients into three distinct prognostic groups with very good, good, or poor prognosis (",
"      <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"       table 6",
"      </a>",
"      ). These prognostic categories are then used as the basis for treatment selection, a process referred to as risk-adapted therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognostic stratification scheme for risk-adapted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/1\">",
"      Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/2\">",
"      Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/3\">",
"      Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/4\">",
"      Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005; 23:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/5\">",
"      Months SR, Raney RB. Rhabdomyosarcoma of the head and neck in children: the experience at the Children's Hospital of Philadelphia. Med Pediatr Oncol 1986; 14:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/6\">",
"      Hicks J, Flaitz C. Rhabdomyosarcoma of the head and neck in children. Oral Oncol 2002; 38:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/7\">",
"      Shapiro E, Strother D. Pediatric genitourinary rhabdomyosarcoma. J Urol 1992; 148:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/8\">",
"      Lawrence W Jr, Hays DM, Moon TE. Lymphatic metastasis with childhood rhabdomyosarcoma. Cancer 1977; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/9\">",
"      Lawrence W Jr, Gehan EA, Hays DM, et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987; 5:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/10\">",
"      Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 2001; 10:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/11\">",
"      Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2011; 29:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/12\">",
"      Raney RB Jr, Tefft M, Maurer HM, et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1988; 62:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/13\">",
"      Koscielniak E, Rodary C, Flamant F, et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 1992; 20:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/14\">",
"      Ruymann FB, Newton WA Jr, Ragab AH, et al. Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study. Cancer 1984; 53:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/15\">",
"      Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/16\">",
"      Spunt SL, Anderson JR, Teot LA, et al. Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside of the head and neck region that is metastatic at diagnosis: a report from the Intergroup Rhabdomyosarcoma Study Group. Cancer 2001; 92:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/17\">",
"      McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005; 184:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/18\">",
"      Klem ML, Grewal RK, Wexler LH, et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007; 29:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/19\">",
"      V&ouml;lker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/20\">",
"      Ben Arush MW, Bar Shalom R, Postovsky S, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol 2006; 28:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/21\">",
"      Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin Nucl Med 2006; 31:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/22\">",
"      Kawasaki H, Takayama J, Nagasaki K, et al. Hypercalcemia in children with rhabdomyosarcoma. J Pediatr Hematol Oncol 1998; 20:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/23\">",
"      Fiegl M, Weltermann A, Stindl R, et al. Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature. Ann Hematol 1999; 78:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/24\">",
"      Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/25\">",
"      Rodary C, Gehan EA, Flamant F, et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 1991; 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/26\">",
"      La Quaglia MP, Heller G, Ghavimi F, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 1994; 73:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/27\">",
"      Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/28\">",
"      Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18327/abstract/29\">",
"      Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006; 24:3844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7728 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18327=[""].join("\n");
var outline_f17_57_18327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8829029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Presentation by anatomic site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Head and neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Extremities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Regional nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Distant metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL DIAGNOSTIC AND STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Metastatic workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H719050272\">",
"      - Lymph node assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      STAGING AND PROGNOSTIC STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical grouping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TNM system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognostic stratification scheme for risk-adapted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8829029\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/3/17468\" title=\"table 1\">",
"      Prognosis RMS by primary site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/10/42155\" title=\"table 2\">",
"      Tissue process soft tissue mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/31/1531\" title=\"table 3\">",
"      Diagnostic studies RMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/41/32411\" title=\"table 4\">",
"      Clinical group rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/13/7389\" title=\"table 5\">",
"      Rhabdomyosarcoma TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/52/11086\" title=\"table 6\">",
"      Rhabdomyosarc prognos stratify",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18328="Control of ventricular rate in atrial flutter";
var content_f17_57_18328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Control of ventricular rate in atrial flutter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18328/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/57/18328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventricular response to atrial flutter is variable, as it is atrial fibrillation. It is determined by the number of impulses conducted through the atrioventricular (AV) node unless there is an accessory pathway.",
"   </p>",
"   <p>",
"    The physiologic and clinical rationales for ventricular rate control in atrial flutter and the modalities used to achieve this goal will be reviewed here. Other issues such as the causes of atrial flutter, the embolic risk associated with this arrhythmia, and the restoration and maintenance of sinus rhythm are discussed separately on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC RATIONALE FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventricular response in atrial flutter is influenced by several factors that may determine the approach to therapy. These factors apply to both types of atrial flutter: type I (typical, common, or isthmus-dependent) and type II (atypical or non-isthmus-dependent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Even and odd ventricular responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventricular response in atrial flutter is generally one-half the atrial input. Thus, the ventricular rate is usually about 150",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    at the average type I atrial rate of 300",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    A higher degree of AV block (eg, 3:1 or 4:1) suggests AV nodal disease in the absence of drugs that slow AV nodal conduction; in these settings the ventricular rates would be roughly 100 and 75",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Thus, heart rates of 150, 100, and 75",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    in the presence of AV block should suggest type I atrial flutter to the interpreter of the ECG. In such patients, drugs that slow AV conduction further should be used with caution. The atrial rates (340 to 440",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    and therefore the ventricular rates at similar degrees of AV block are higher in type II flutter.",
"   </p>",
"   <p>",
"    For reasons discussed elsewhere, even",
"    <span class=\"nowrap\">",
"     input/output",
"    </span>",
"    ratios (eg, 2:1 or 4:1 conduction) are much more common than odd ratios (eg, 3:1 or 5:1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .) Odd ratios probably reflect bilevel block in the AV node. On the other hand, a 1:1 response suggests possible hyperthyroidism, catecholamine excess, parasympathetic withdrawal, or the existence of an accessory bypass tract in the preexcitation syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electrophysiologic and autonomic influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AV node has been called a \"slow response\" tissue, since its action potential depends on calcium ions flowing through kinetically slow channels. (",
"    <a class=\"graphic graphic_figure graphicRef75699 \" href=\"UTD.htm?38/48/39695\">",
"     figure 1",
"    </a>",
"    ) The activation and reactivation characteristics of these channels limits the rate of conduction through the AV node. The autonomic nervous system can modify the rate of conduction, which is increased by sympathetic activity and reduced by parasympathetic activity.",
"   </p>",
"   <p>",
"    It is useful to consider the electrophysiologic differences between atrial fibrillation (AF) and atrial flutter, since they can impact on therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AF is characterized by multiple wandering wavelets, which result in the AV node being bombarded by 400 to 600 impulses per minute. Some impulses traverse the AV node and reach the specialized infranodal conduction system and then the ventricles. However, most of the atrial impulses penetrate the AV node for varying distances and then are extinguished by encountering the refractoriness of an earlier wavefront; this phenomenon of concealed conduction in turn creates a refractory wave that affects succeeding impulses. The lack of shortening of the refractory period with increasing rate (as occurs in the atria) further decreases the likelihood of an impulse traversing the AV node. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"       \"The electrocardiogram in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In comparison, typical atrial flutter is a macroreentrant arrhythmia, resulting in only 300",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      reaching the AV node. This slower rate produces less refractoriness within the AV node and therefore less concealed conduction than in AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, it would be expected that AF would be more sensitive than atrial flutter to drugs that affect AV nodal refractoriness; this prediction has been confirmed clinically. Large doses of AV nodal blockers used as monotherapy are often required to slow the AV conduction ratio in atrial flutter from 2:1 to 4:1. Difficulties with pharmacologic rate control and an alternative curative approach make patients with atrial flutter excellent candidates for a curative catheter ablation procedure (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Radiofrequency ablation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL RATIONALE FOR AND DEFINITION OF RATE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two important reasons to prevent a rapid ventricular response in patients with atrial flutter: avoidance of hemodynamic instability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms such as palpitations, heart failure, lightheadedness, and poor exercise capacity: and, over the longer term, avoidance of a tachycardia-mediated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rate control should be assessed both at rest and with exertion. Although rate control targets have been described for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/1\">",
"     1",
"    </a>",
"    ], they are less useful in atrial flutter since, as noted above, AV block tends to go in steps. Thus, 2:1, 3:1, and 4:1 AV block would, in type 1 atrial flutter, be associated with ventricular rates of roughly 150, 100, and 75",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic strategies for controlling the ventricular rate in atrial flutter are based on these physiologic properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockade of the calcium channel with the nondihydropyridine calcium channel blockers",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Decreased sympathetic tone resulting from beta blockade as produced by short, moderate, and long acting drugs.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , which slows AV nodal conduction and increases AV nodal refractoriness.",
"     </li>",
"     <li>",
"      Enhancement of parasympathetic tone with vagotonic drugs, the most important of which is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A combination of the above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to therapy is similar to that in AF. We generally agree with the approach of the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines on atrial fibrillation&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, as discussed above, the smaller amount of concealed conduction in the AV node because of the slower atrial rate in atrial flutter means that",
"    <strong>",
"     greater AV nodal refractoriness",
"    </strong>",
"    must be produced. As a result, higher doses of a single drug are required, and combination therapy at conventional doses is an attractive option to minimize toxicity.",
"   </p>",
"   <p>",
"    Nonpharmacologic therapy including DC cardioversion, pace termination, or curative catheter ablation are reasonable treatments if the patient is having adverse hemodynamic consequences from the arrhythmia, if pharmacologic therapies are unsuccessful or not tolerated, or if the patient has preexcitation syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Caution in preexcitation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with atrial flutter and preexcitation, therapy is aimed at reversion to sinus rhythm and subsequent treatment of the accessory pathway rather than rate control. The AV nodal blocking drugs (calcium channel blockers, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) can paradoxically increase the ventricular response in patients with atrial flutter and preexcitation by impairing conduction via the normal AV node-His-Purkinje system. This decreases retrograde concealed conduction in the accessory pathway, thereby improving antegrade conduction over the pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\", section on 'Avoidance of AV nodal blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nondihydropyridine calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    are useful for acute rate control in non-preexcited atrial flutter when given intravenously and can produce long-term rate slowing when given orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=see_link\">",
"     \"Calcium channel blockers in the treatment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    is often the drug of choice for acutely controlling the rapid ventricular response in atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Diltiazem increases AV nodal refractoriness and slows conduction velocity in the AV node, thereby decreasing the ventricular response. Diltiazem has a less pronounced negative inotropic effect than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a Food and Drug Administration (FDA) approved regimen for a continuous, 24 hour intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    infusion that is derived from the Diltiazem Atrial",
"    <span class=\"nowrap\">",
"     Fibrillation/Atrial",
"    </span>",
"    Flutter Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This regimen consists of an intravenous bolus of 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (average adult dose 20 mg) over two minutes followed in 15 minutes by a second bolus of 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (average adult dose 25 mg) over two minutes if the first dose is tolerated but does not produce the desired response (20 percent reduction in heart rate from the baseline, conversion to sinus rhythm, or a heart rate less than 100",
"    <span class=\"nowrap\">",
"     beats/min);",
"    </span>",
"    this is followed by a continuous infusion at a rate of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    in responders but not nonresponders; some patients respond to a 5",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/5\">",
"     5",
"    </a>",
"    ]. This regimen usually controls the ventricular rate within four to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monotherapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    can be used to treat patients with chronic atrial flutter, as well as patients who have recurrent or chronic atrial fibrillation with episodic atrial flutter. The initial dose is 30 mg every six hours, and is increased to a maximum of 360",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Sustained release diltiazem is most commonly used as a once a day drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , increases refractoriness and decreases conduction velocity in the AV node, leading to reductions in the ventricular response in atrial flutter as well as atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Intravenous verapamil can be given acutely in a dose of 5 to 10 mg over two to three minutes; this dose can be repeated every 15 to 30 minutes, as necessary. The maintenance infusion rate is approximately 0.125",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"    The onset of action is within two minutes and the peak effect occurs in 10 to 15 minutes. Control of the ventricular response is lost in roughly 90 minutes if repeated boluses or a maintenance infusion are not given.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    may be used to treat patients with chronic atrial flutter or patients with recurrent or chronic atrial fibrillation who has episodic atrial flutter the initial dose of oral verapamil is 40 to 80 mg every six hours. This dose can be increased to a maximum of 360",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if hepatic function is relatively normal. The sustained-release formulation is used for chronic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical cautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers have a number of characteristics that need to be considered with when they are administered to patients with atrial flutter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect on sinoatrial (SA) nodal function is variable. Although both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      have an inhibitory effect on the sinus node (which generates a slow action potential mediated by calcium fluxes), their vasodilator effects cause a reflex release of catecholamines that usually maintain or slightly accelerate the SA nodal rate. However, SA nodal function is depressed in patients with the sick sinus syndrome, at least in part due to blockade of calcium channels and an inability of the sinus node to respond to catecholamines. Thus, if the normal reflex mechanism is impaired by therapy with a beta blocker, the addition of a calcium channel blocker can lead to slowing or, rarely, failure of SA nodal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      perhaps more than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , can produce high-degree AV block and therefore should not be given to patients with underlying second- or third-degree AV block. For similar reasons, calcium channel blockers must be used with caution when given with other drugs that slow AV nodal conduction (eg, beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      has a negative inotropic effect that is more pronounced than that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      . As a result, it should be used with caution in patients with heart failure and should not be given if the patient is hypotensive. It should also be used cautiously with other negative inotropes, such as beta blockers.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      interacts with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , resulting in an increase in serum digoxin. This interaction is dose-related (often occurring when verapamil doses are over 240",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and generally occurs after seven days of therapy with both agents. Similar to the digoxin-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      interaction, verapamil reduces the renal clearance of digoxin; it may also interfere with its hepatic metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with severe heart failure (NYHA class III or IV) and should be given with caution to patients with sinus node dysfunction, second- or third-degree AV block, the preexcitation syndrome, hypotension, or the concurrent intake of other drugs that inhibit SA nodal function or slow AV nodal conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Esmolol and other beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     Esmolol",
"    </a>",
"    , a rapidly acting beta blocker that is administered intravenously, is useful for rate control in acute non-preexcited atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Esmolol begins to act in one to two minutes, is metabolized by red blood cell esterase, and has a short duration of action of 10 to 20 minutes. The following esmolol regimen is recommended for acute rate control:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A bolus of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is infused over one minute, followed by 50",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If, after four minutes, the response is inadequate, another bolus is given followed by an infusion of 100",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If, after four minutes, the response is still inadequate, a third and final bolus can be given followed by an infusion of 150",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If necessary, the infusion can be increased to a maximum of 200",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min after another four minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, an infusion can be started at 50",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min without a bolus, and the rate of administration can be increased by 50",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min every 30 minutes.",
"   </p>",
"   <p>",
"    There is little literature on the use of oral beta blockers as primary therapy for atrial flutter. Anecdotal reports suggest that these drugs can slow the ventricular rate, particularly if given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Beta blockers may have a variety of adverse effects. Some of these complications may be important in patients with atrial flutter including worsening heart failure, hypotension, bradycardia, bronchospasm, and high-degree AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    historically was the most commonly used drug to control the ventricular rate in atrial flutter in the nonemergent setting. However, calcium channel blockers and beta blockers, singly or in combination, have largely supplanted digoxin for both initial intravenous rate control and, if necessary, for chronic oral therapy. One setting in which digoxin may be first-line therapy is in patients with heart failure; digoxin can also be given with a calcium channel blocker or beta blocker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    can be administered orally, intravenously, or intramuscularly, although we do not use the intramuscular route because absorption is erratic. Intravenous digoxin begins to act within 15 to 30 minutes, with a peak effect attained in one to five hours. The relatively slow onset of action of digoxin is undesirable in patients with a rapid ventricular response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A larger dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    than used in atrial fibrillation is required to control the ventricular rate in atrial flutter; as noted above, the smaller amount of concealed conduction in the AV node because of the slower atrial rate in atrial flutter means that greater AV nodal refractoriness must be produced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/17\">",
"     17",
"    </a>",
"    ]. Serum digoxin levels should be monitored periodically in patients on chronic therapy. Although the correlation between drug concentration and ventricular rate control is poor, the presence of a low value is useful since it allows a higher dose to be administered. The use of high doses of digoxin is potentially hazardous if electric cardioversion is performed, since this combination increases the risk of serious ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Junctional escape beats (as detected by similarity of the longest observed recurring RR intervals on the ECG) are common when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    has successfully slowed the ventricular rate. Giving additional digoxin in this setting will increase the degree of AV nodal block and produce periods of regular junctional rhythm. The change from single junctional escapes to periodic junctional rhythm usually signifies the development of digoxin toxicity. If the pulse is palpated but ECG not reviewed, it may be mistakenly assumed that the patient is in sinus rhythm.",
"   </p>",
"   <p>",
"    However, it may be difficult to distinguish on the ECG between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -induced complete heart block during atrial flutter and a slow, regular ventricular rate. In complete heart block, the R-R interval will not be an exact multiple of the atrial cycle length (A-A interval). In addition, the relationship between the QRS complex and flutter wave (ie, the point on the flutter wave where the QRS complex begins) is variable during complete heart block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H7983933#H7983933\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Effect of high degrees of AV nodal block and exit block on ventricular response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    slows conduction through the AV node and prolongs the effective refractory period of the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/18\">",
"     18",
"    </a>",
"    ]. It has been used for rate control in critically ill patients with atrial tachyarrhythmias, mostly atrial fibrillation with some cases of atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This includes patients with heart failure, since amiodarone has less negative inotropic activity than beta blockers or calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of slowing of the ventricular rate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    were compared in a study of 60 critically ill patients with recent onset atrial tachyarrhythmias, almost all atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/20\">",
"     20",
"    </a>",
"    ]. Amiodarone was given as a 300 mg bolus, with or without a continuous infusion of 45",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    for 24 hours. Diltiazem was given as an 25 mg bolus, followed by a continuous infusion of 20",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    for 24 hours. Rate control was achieved with both drugs; the degree of slowing was somewhat better with diltiazem, an effect that was offset by a significantly higher incidence of hypotension that required discontinuation of diltiazem.",
"   </p>",
"   <p>",
"    Although it is not very effective, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    can promote reversion to sinus rhythm. Since cardioversion is associated with an increased risk of thromboembolism, amiodarone should generally not be used in patients who are not candidates for conversion to sinus rhythm because of inadequate anticoagulation. Standard AV nodal blockers should be used in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701799#H8701799\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Amiodarone (intravenous)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701807#H8701807\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Amiodarone (oral)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is an alternative in patients with atrial flutter and severe hemodynamic compromise, although it has not been approved by the Food and Drug Administration for this purpose. Because of the long-term risk of adverse effects, amiodarone is not recommended for chronic rate control in patients with atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class IA (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and class IC antiarrhythmic drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) are often administered in an attempt to convert atrial fibrillation to atrial flutter or to maintain sinus rhythm after successful reversion of one of these arrhythmias. These drugs block the sodium channel, thereby decreasing the rapid inward sodium current that is responsible for phase 0 depolarization in atrial tissue; this change, in turn, slows the atrial flutter rate by reducing the conduction velocity in the atrial reentrant circuit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .) As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , the risk of thromboembolism due to cardioversion should be considered before administering a class I or II agent to a patient in atrial fibrillation or flutter.",
"   </p>",
"   <p>",
"    Class IA drugs also have a vagolytic effect that can enhance AV nodal conduction. The effect of slowing the flutter rate in the presence of enhanced AV nodal conduction may lead to 1:1 AV conduction of atrial flutter at rapid rates (",
"    <a class=\"graphic graphic_waveform graphicRef55441 \" href=\"UTD.htm?14/20/14662\">",
"     waveform 1",
"    </a>",
"    ). Thus, a drug that slows AV nodal conduction (beta blocker, calcium channel blocker, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) should be given in conjunction with the class IA drugs to prevent this occurrence.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    may promote the appearance of \"slow\" atrial flutter in patients with atrial tachyarrhythmia. However, 1:1 AV conduction is generally not a problem in this setting due to the inhibitory effect of amiodarone on AV nodal conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation of the AV junction (AV node",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    His bundle) can be performed in patients with atrial flutter in whom rate control is difficult to achieve [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18328/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This approach, which is primarily used in patients with atrial fibrillation, usually induces complete heart block requiring insertion of a permanent pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablation of the AV junction is not often performed in patients with atrial flutter because of the high rate of success with radiofrequency ablation of the reentrant circuit to maintain sinus rhythm. The main indication for AV junction ablation is in patients with atrial flutter who have coincident atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations should be considered as general guidelines for controlling the ventricular rate in atrial flutter; they may need to be amended in individual patients with a particular confounding factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Preference for sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal outcome of atrial flutter is reversion to and maintenance of normal sinus rhythm, not ventricular rate control.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In terms of reversion, DC cardioversion is the procedure of choice for reversion to sinus rhythm if the patient is hemodynamically unstable and is not instrumented. On the other hand, atrial overdrive pacing with entrainment may be preferable in the patient who has recurrent episodes of atrial flutter, particularly if hemodynamically unstable; this problem may occur after cardiac surgery or a myocardial infarction. Stable patients may convert after watchful waiting or DC cardioversion or pharmacologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In terms of maintenance of sinus rhythm, we generally attempt to cure the atrial flutter by ablating the reentrant circuit in patients with recurrent arrhythmia that is not due to reversible cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"       \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous calcium channel blockers or beta blockers may be used as described above if rapid control of the ventricular response is required. However, attention must be paid to the potential deleterious adverse effects of these drugs. As discussed above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is not typically used as first-line therapy, except in patients with heart failure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is also effective for control of the rapid ventricular response associated with atrial fibrillation and atrial flutter, particularly in the hemodynamically compromised patient. One concern with amiodarone is that it may promote conversion to sinus with a consequent increase in risk of embolization if the patient is not anticoagulated.",
"   </p>",
"   <p>",
"    Hospital admission for intravenous therapy may not be necessary in patients who are clinically stable. Such patients can be treated with oral AV nodal blockers and oral anticoagulant therapy, and scheduled for elective cardioversion or curative ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic therapy to control the ventricular response is generally difficult in patients with atrial flutter. It is becoming a less common problem since, in most patients with chronic atrial flutter, we attempt to cure the arrhythmia by ablating the reentrant circuit. An exception to this general rule may occur if rapid atrial flutter is part of paroxysmal atrial fibrillation or the sick sinus syndrome. Treatment in the former setting is essentially that for atrial fibrillation. However, patients with both atrial fibrillation and atrial flutter may benefit from ablation of the flutter circuit if rapid ventricular responses during atrial flutter are symptomatic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      have the advantage of a long half-life, and atenolol, in our experience, has the least adverse effect on the sensorium. Long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      preparations are also effective. We generally begin with atenolol, 25",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and increase the daily dose to 100 mg and sometimes 200 mg, if necessary. Beta blockers are particularly useful for patients who also have coronary artery disease or chronic heart failure.",
"     </li>",
"     <li>",
"      Among the calcium channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      has a somewhat greater blocking effect on the AV node than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , and the choice between these agents is often dictated by side effects. A calcium channel blocker is preferred to a beta blocker in patients with chronic lung disease.",
"     </li>",
"     <li>",
"      As in atrial fibrillation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is used less often than beta blockers or calcium channel blockers for rate control, because its major action is enhancement of vagal tone, which is offset during exertion. It is still given in patients with heart failure, often in combination with another drug that decreases AV nodal conduction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      helps maintain normal sinus rhythm and, should atrial fibrillation or atrial flutter recur, generally controls the ventricular response. However, the risk of adverse effects makes amiodarone a poor choice for long-term rate control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/1\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/2\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/3\">",
"      Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/4\">",
"      Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991; 18:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/5\">",
"      Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol 1995; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/6\">",
"      B&ouml;hm M, Schwinger RH, Erdmann E. Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 1990; 65:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/7\">",
"      Dominic J, McAllister RG Jr, Kuo CS, et al. Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther 1979; 26:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/8\">",
"      Tommaso C, McDonough T, Parker M, Talano JV. Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. Arch Intern Med 1983; 143:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/9\">",
"      Hwang MH, Danoviz J, Pacold I, et al. Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery. Arch Intern Med 1984; 144:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/10\">",
"      Plumb VJ, Karp RB, Kouchoukos NT, et al. Verapamil therapy of atrial fibrillation and atrial flutter following cardiac operation. J Thorac Cardiovasc Surg 1982; 83:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/11\">",
"      Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/12\">",
"      Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982; 65:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/13\">",
"      Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/14\">",
"      Hedman A, Angelin B, Arvidsson A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991; 49:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/15\">",
"      Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/16\">",
"      Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest 1988; 93:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/17\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/18\">",
"      Morady F, DiCarlo LA Jr, Krol RB, et al. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986; 7:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/19\">",
"      Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/20\">",
"      Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/21\">",
"      Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/22\">",
"      Scheinman MM, Evans-Bell T. Catheter ablation of the atrioventricular junction: a report of the percutaneous mapping and ablation registry. Circulation 1984; 70:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18328/abstract/23\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1067 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18328=[""].join("\n");
var outline_f17_57_18328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC RATIONALE FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Even and odd ventricular responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electrophysiologic and autonomic influences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL RATIONALE FOR AND DEFINITION OF RATE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Caution in preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diltiazem",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical cautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Esmolol and other beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Preference for sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic rate control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1067|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39695\" title=\"figure 1\">",
"      AV nodal physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1067|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/20/14662\" title=\"waveform 1\">",
"      Type I atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=related_link\">",
"      Calcium channel blockers in the treatment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=related_link\">",
"      Treatment with digoxin: initial dosing, monitoring, and dose modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18329="Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening";
var content_f17_57_18329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Jacob A Canick, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Geralyn M Messerlian, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Antonio Farina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18329/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/57/18329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women are routinely offered prenatal serum screening for Down syndrome and neural tube defects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the primary aim of this policy is to detect these disorders, abnormal maternal analyte screening results are also associated with increased risks of other chromosomal and anatomic abnormalities, as well as some adverse pregnancy outcomes.",
"   </p>",
"   <p>",
"    Selected adverse fetal and pregnancy outcomes predicted by maternal analyte screening will be reviewed here. Prenatal serum screening for Down syndrome and neural tube defects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MARKERS USED FOR DOWN SYNDROME SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum analytes obtained in first trimester Down syndrome screening include pregnancy-associated plasma protein-A (PAPP-A) and either total beta- or free beta-human chorionic gonadotropin (beta-hCG). The combined test (sonographic measurement of fetal nuchal translucency and maternal serum assessment of beta-hCG and PAPP-A) detects 85 percent of Down syndrome fetuses at a 5 percent false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The first trimester analyte pattern of trisomy 21 is low PAPP-A (median 0.4 MoM), high beta-hCG (median about 1.8 MoM for free beta-hCG and 1.4 MoM for total beta-hCG), and increased nuchal translucency (median 2.0 MoM) (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the second trimester, serum alpha-fetoprotein (AFP) levels are used to screen for open neural tube defects. Levels above 2.0 or 2.5 MoM indicate pregnancies at increased risk of spina bifida or anencephaly. Screening for Down syndrome can also be achieved in the second trimester with the quad screen, which uses maternal age in combination with serum AFP, unconjugated estriol (uE3), beta-hCG and inhibin A. Maternal serum levels of AFP and uE3 are, on average, reduced by 30 percent in affected pregnancies, while levels of beta-hCG and inhibin A are increased approximately two-fold. The quad screen can detect about 85 percent of Down syndrome pregnancies at a 7 percent false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best screening performance for Down syndrome is achieved by integrating first and second trimester markers into a single risk assessment. The integrated test detects 85 to 90 percent of Down syndrome fetuses at a 1 to 2 percent false positive rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FIRST TRIMESTER MARKERS AND OTHER FETAL ANEUPLOIDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programs that offer trisomy 21 screening in the first trimester usually include an algorithm to assess risk of trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/5\">",
"     5",
"    </a>",
"    ]. Some programs provide risk estimates for trisomy 13, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/6\">",
"     6",
"    </a>",
"    ]. The expectation is that risk assessment for trisomies 18 and 13 will add very little to the overall false positive rate (&lt;1 percent) and identify more than 70 percent of affected pregnancies.",
"   </p>",
"   <p>",
"    Assessment for the presence or absence of ultrasonographic markers improves diagnostic performance. Although Turner syndrome and triploidy lead to changes in first trimester screening marker levels, suspicion of these aneuploidies is typically based on ultrasound screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H23#H23\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 18'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H24#H24\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 13'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H26#H26\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Turner syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H25#H25\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Triploidy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trisomy 18",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trimester analyte pattern of trisomy 18 is very low PAPP-A (median 0.1 - 0.2 MoM), very low beta-hCG (median 0.2 - 0.4 MoM) and increased nuchal translucency (median 1.8 - 3.7 MoM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 1",
"    </a>",
"    ). Estimates are that about 90 percent of trisomy 18 pregnancies can be identified with less than a 1 percent false positive rate using first trimester screening [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trisomy 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trimester analyte pattern of trisomy 13 is similar to that of trisomy 18, but more variable. It is characterized by low to very low PAPP-A (median 0.36 MoM) and free beta-hCG (median 0.41 MoM) and a modestly increased nuchal translucency (median 1.17 MoM, range 0.63 to 4.5) (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/7\">",
"     7",
"    </a>",
"    ]. Performance of trisomy 13 screening should be similar to, though lower than, that of trisomy 18. However, one study estimated that 87 percent of trisomy 13 cases could be detected in the first trimester with a 0.2 percent false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Triploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triploidy (69,XXX; 69,XXY; 69,XYY) can affect analytes measured in Down syndrome screening. The two types of triploidy are based upon the parental origin of the extra set of chromosomes.",
"   </p>",
"   <p>",
"    Type I triploidy (diandric) originates from an extra set of paternal chromosomes and is characterized by a large cystic placenta and fetal loss early in gestation. In one study, first trimester median levels were 8.7 MoM for free beta-hCG and 0.74 MoM for PAPP-A in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/11\">",
"     11",
"    </a>",
"    ]. Type II triploidy (digynic) originates from an extra set of maternal chromosomes and is characterized by a small fetus, small placenta, and intrauterine survival late into pregnancy. In the same study, first trimester median levels were extremely low, 0.16 MoM for free beta-hCG and 0.06 MoM for PAPP-A, in such cases. Using risk algorithms for trisomy 21, 18, and 13 in combination resulted in detection of 84 percent of triploidy cases at a 3.1 percent false positive rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318209\">",
"    <span class=\"h2\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancies affected by fetal Turner's syndrome (45,X) have relatively normal serum PAPP-A levels (median 0.99 MoM), with slightly increased free beta-hCG (median 1.20 MoM) and NT (median 1.38 MoM) levels. There are no published estimates of the performance of first trimester screening markers for Turner syndrome alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SECOND TRIMESTER MARKERS AND OTHER FETAL ANEUPLOIDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal abnormalities, other than Down syndrome, identified by routine prenatal maternal serum screening in the second trimester, are described below. A summary of the serum marker patterns for various cytogenetic and genetic abnormalities is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trisomy 18",
"    </span>",
"    &nbsp;&mdash;&nbsp;The analyte pattern suggestive of trisomy 18 is low levels of AFP, uE3, and beta-hCG. The reduction in analyte levels is, on average, 40 percent for AFP, 60 percent for uE3, and 70 percent for beta-hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/12\">",
"     12",
"    </a>",
"    ]. The concentration of inhibin A is only slightly reduced (by 12 to 16 percent), thus it is not used in screening for trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on this analyte pattern, maternal age and levels of AFP, uE3, and beta-hCG (triple screen (",
"    <a class=\"graphic graphic_table graphicRef76911 \" href=\"UTD.htm?34/33/35355\">",
"     table 2",
"    </a>",
"    )) can be used to generate a patient-specific risk for trisomy 18, and will detect 60 to 80 percent of fetuses with trisomy 18, with a very low screen positive rate of about 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/12\">",
"     12",
"    </a>",
"    ]. By comparison, the combination of maternal age and characteristic fetal structural malformations on ultrasound examination has detected 82 percent of these fetuses at a 4 percent false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H23#H23\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 18'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Trisomy 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current second trimester prenatal serum screening protocols do not detect affected pregnancies, as there is no consistent alteration of serum analyte concentrations in women carrying a fetus with trisomy 13, with the exception of a slight reduction (about 10 percent) in uE3 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/16\">",
"     16",
"    </a>",
"    ]. However, over 90 percent of cases will have abnormalities on ultrasound examination, and often have multiple severe structural malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H24#H24\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 13'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus with Turner syndrome (45,X) may or may not exhibit hydrops.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal Turner syndrome complicated by hydrops has a maternal serum marker pattern similar to that observed with Down syndrome, with relatively low uE3 (median 0.61 MoM) and elevated beta-hCG (median 5.05 MoM) and inhibin A (median 3.91 MoM) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/14,18,19\">",
"       14,18,19",
"      </a>",
"      ]. AFP levels are low or normal (median range 0.8 to 1.0 MoM).",
"     </li>",
"     <li>",
"      Turner syndrome without hydrops is characterized by moderately reduced levels of all analytes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/14,18,19\">",
"       14,18,19",
"      </a>",
"      ], similar to the pattern seen with trisomy 18. Median levels of AFP, uE3 and inhibin A are about 0.6 MoM and median beta-hCG is about 0.8 MoM in cases of Turner syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetal Turner syndrome tends to be identified in women undergoing diagnostic testing because of high risk of Down syndrome or trisomy 18, although performance estimates have not been reported. In addition, it may be suspected sonographically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"     \"Second trimester maternal serum screening for Down syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H26#H26\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Turner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Triploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a pregnancy affected by triploidy continues to the second trimester, screening results for cases of Type I triploidy (diandric) will often indicate a high risk of Down syndrome because of low uE3 and elevated beta-hCG and inhibin A concentrations in maternal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. AFP levels in triploidy are not predictable; they may be high, low or unremarkable.",
"   </p>",
"   <p>",
"    Maternal serum levels of uE3 are extremely low (usually less than 20 percent of normal values) in Type II triploidy (digynic) and beta-hCG and inhA are also reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. AFP levels are not predictable. These cases may be identified by second trimester trisomy 18 screening protocols. The&nbsp;integrated test may provide similar or improved screening performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FIRST TRIMESTER MARKERS AND ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies describing the association between individual low or elevated levels of Down syndrome screening markers and adverse pregnancy outcome appear regularly in the literature. However, it is unclear whether any type of monitoring and intervention protocol when abnormal markers levels are detected will lead to improved pregnancy outcome and be cost effective. In the absence of such data, there is no evidence that changes in clinical management are indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/22\">",
"     22",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H25\">",
"     'Management'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Low pregnancy associated protein (PAPP)-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low PAPP-A level (less than 0.4 MoM) has been associated with preeclampsia, fetal growth restriction, preterm birth, and fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/23-31\">",
"     23-31",
"    </a>",
"    ]. Although these associations exist at the lower tail of the PAPP-A distribution, the majority of patients with these adverse outcomes do not have a low PAPP-A; therefore, the sensitivity is poor. In addition, few patients with a low PAPP-A actually have an adverse outcome (low positive predictive value).",
"   </p>",
"   <p>",
"    In large first trimester screening trials, adverse outcomes were noted in patients with extreme PAPP-A levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. For example, in 8000 women with a live fetus between 11 and 14 weeks of gestation, very low PAPP-A levels (less than the 5th percentile, &lt;0.45 MoM) were associated with a 1 to 4 percent risk of pregnancy loss before 20 weeks, depending upon the degree of reduction of the marker [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. PAPP-A less than the 1st percentile (&lt;0.29 MOM) and PAPP-A less than the 5th percentile (&lt;0.45 MOM) were also associated with significantly increased risk of intrauterine growth restriction, with positive predictive values of 24 and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Low beta-hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse outcomes have been noted in patients with extreme low first trimester free beta-hCG levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. For example, women with free beta-hCG levels less than the 5th percentile (&lt;0.38 MoM) had a 1 to 4 percent risk of pregnancy loss before 20 weeks, depending upon the degree of reduction of the marker [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Free beta-hCG less than the 1st percentile (&lt;0.21 MOM) was associated with a significantly increased risk of intrauterine growth restriction, with positive predictive value of 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     High PAPP-A or high beta-hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known relationship between high PAPP-A or beta-hCG levels and adverse outcome, unless the high hCG is associated with gestational trophoblastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/29,32,33\">",
"     29,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SECOND TRIMESTER MARKERS AND ADVERSE OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Low alpha fetoprotein (AFP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study that followed 77,149 pregnant women and their infants from AFP screening in the 15th to 20th week of gestation until one year after birth observed that AFP levels below 0.25 MoM were associated with significantly increased relative risks (RR) of spontaneous abortion (RR 15), preterm birth (RR 2), and stillbirth (RR 4), and those with levels less than 0.5 MoM had an increased risk of infant death (RR 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/34\">",
"     34",
"    </a>",
"    ]. A retrospective case-control study observed that non-diabetic women with unexplained very low AFP levels (&le;0.25 MoM) were at increased risk of delivering a macrosomic infant compared to normal controls (26 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     High AFP",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated AFP level (&gt;2.0 MoM) in the second trimester that cannot be explained (eg, presence of a fetal anomaly, inaccurate gestational dating, multiple gestation, maternal hepatocellular or ovarian tumor) is associated with an increased risk of subsequent fetal death, particularly in pregnancies complicated by hypertension. A high AFP value has also been associated with a variety of major congenital anomalies, low birth weight, and abruptio placentae. The mechanism for poor pregnancy outcome in these cases may relate to defective placentation leading to higher than normal fetal to maternal AFP transport. Some specific examples worth noting:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318317\">",
"    <span class=\"h3\">",
"     Placenta accreta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 50 percent of patients with placenta accreta have an elevated AFP level. Although placenta accreta is rare, evaluation of the uteroplacental interface is warranted in women with an unexplained elevated AFP, particularly in the setting of a placenta previa and previous cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318324\">",
"    <span class=\"h3\">",
"     Fetal anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated AFP is a marker for open neural tube defects, but several other fetal anatomical defects are associated with this finding. AFP is raised in the majority of pregnancies with fetal omphalocele (median 4 MoM), and in essentially all pregnancies with gastroschisis (median 10 MoM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/36\">",
"     36",
"    </a>",
"    ]. Fetal teratomas, cystic hygroma, benign obstructive uropathy, and other abnormalities characterized by fetal edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin defects can also be associated with elevated maternal serum AFP levels. Many of these abnormalities can be detected by prenatal ultrasound examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318331\">",
"    <span class=\"h3\">",
"     Congenital nephrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital nephrosis (Finnish type) is an autosomal recessive disease that leads to fetal proteinuria and death within months of birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    .) Most affected pregnancies are associated with markedly increased second trimester AFP levels (9 MoM or higher) in the absence of structural defects (abdominal wall defects, NTDs) on ultrasound examination. Cases of congenital nephrosis can be differentiated from nonvisualized open neural tube defects by an absent acetylcholinesterase enzyme result concurrent with a very high amniotic fluid AFP level (&gt;5 MoM), but diagnosis requires confirmation by mutation analysis for the nephrin gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34247?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Low unconjugated estriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low uE3 level (&le;0.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or &le;0.15 MoM) has been associated with fetal steroid sulfatase deficiency, early fetal death, and adrenal hypoplasia, as well as Smith-Lemli-Opitz syndrome. In one series of 103 cases of unexplained low uE3, 41 fetal demises occurred and 39 of these were at or before 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/37\">",
"     37",
"    </a>",
"    ]. In almost all of these cases, there were additional maternal analyte abnormalities. Others have observed low uE3 levels in the second trimester associated with fetal growth restriction; the risk appeared to be independent of risk associated with elevated AFP or beta-hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Another study that summarized the findings on low uE3 and pregnancy and fetal disorders provided evidence that pregnancies in which uE3 is undetectable or very low, but the second trimester test is not screen positive, are at sufficiently high risk of serious fetal abnormalities other than steroid sulfatase deficiency that &ldquo;full investigation appears warranted&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal diagnostic studies for disorders such as X-linked ichthyosis (a scaly appearance of the skin in children and adults), chondroplasia punctata, Kallman syndrome, and contiguous gene deletion syndromes are available and may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H5#H5\">",
"     \"The genodermatoses\", section on 'X-linked ichthyosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318259\">",
"    <span class=\"h3\">",
"     Placental sulfatase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental sulfatase deficiency (also known as X-linked ichthyosis) is caused by an X-linked recessive error in the enzyme, neutral steroid sulfatase (STS). During pregnancy, if placental STS is deficient, there is absence or reduction in the production of unconjugated estrogens. Most cases of STS deficiency can be identified through second trimester multiple marker screening as a result of very low to undetectable levels of unconjugated estriol (&lt;0.15 MoM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While X-linked ichthyosis is the only well-documented clinical manifestation of the deletion or mutation of the STS gene alone, PSD may also be associated with poor ripening of the cervix, leading to a higher than usual rate of cesarean delivery. A larger gene deletion sequence, encompassing the PSD locus as well as contiguous genes, occurs in 8 percent of PSD cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/41\">",
"     41",
"    </a>",
"    ], and is associated with mental retardation and Kallman syndrome. Associations between isolated PSD and increased incidence of attention deficit hyperactivity disorder (ADHD) in children, as well as the contiguous gene deletion and autism, have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318266\">",
"    <span class=\"h3\">",
"     Smith-Lemli-Opitz syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive defect in a cholesterol biosynthetic enzyme, C7-reductase, that leads to intellectual disability, poor growth, and a variety of phenotypic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/44\">",
"     44",
"    </a>",
"    ]. The birth prevalence of SLOS is quite low (less than 1 in 20,000). The second trimester marker pattern associated with SLOS is a very low uE3 level (median 0.21 MoM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/45\">",
"     45",
"    </a>",
"    ] because the steroid precursors required for estriol synthesis are deficient in the fetus (",
"    <a class=\"graphic graphic_figure graphicRef71463 \" href=\"UTD.htm?14/37/14942\">",
"     figure 1",
"    </a>",
"    ), and somewhat low levels of AFP (median 0.72 MoM) and beta-hCG (median 0.76 MoM).",
"   </p>",
"   <p>",
"    Maternal serum screening for SLOS with AFP, uE3, and beta-hCG is expected to be very efficient, with a detection rate of about 60 percent at a 0.3 percent false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/46\">",
"     46",
"    </a>",
"    ]. A trial that attempted to identify Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome included over 1 million pregnant women and reported an 83 percent detection rate at a 0.3 percent false positive rate, although the prevalence of SLOS (1 in 100,000 Caucasians) was lower than expected [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/47\">",
"     47",
"    </a>",
"    ]. Women who were screen positive for SLOS were found to be at a very high risk for other major fetal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal diagnosis of SLOS can be performed by amniocentesis with amniotic fluid measurement of cholesterol and its precursors, 7- and 8-dehydrocholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/49\">",
"     49",
"    </a>",
"    ]. Prenatal diagnosis by molecular and mutation analyses is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     High unconjugated estriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated uE3 levels in the second trimester are not associated with adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Low or high hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low or high second trimester beta-hCG level associated with normal levels of AFP, uE3, and inhibin A does not appear to be associated with an increased risk of adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/38,52,53\">",
"     38,52,53",
"    </a>",
"    ]. Multiple adverse pregnancy outcomes have been reported when the elevated beta-hCG was associated with changes in other markers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain serum markers used for Down syndrome screening are altered in pregnancies that subsequently develop preeclampsia. For example, PAPP-A levels are reduced in the first trimester of pregnancies that develop preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/56\">",
"     56",
"    </a>",
"    ], and second trimester levels of beta-hCG and inhibin A are significantly elevated in such pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. The degree of change in the serum analyte levels is more marked as the interval between sample collection and clinical onset of disease shortens. A triple marker test of uE3, beta-hCG and inhibin A performed at 24 weeks of gestation would detect 55 percent of pregnancies that will develop preeclampsia at a 5 percent screen positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of serum markers and preeclampsia is not sufficiently strong to warrant a change in routine prenatal care, especially since, at this time, there is no way of preventing or delaying onset of the disease. Research is ongoing to improve prenatal screening for preeclampsia with the hope that successful treatments will be developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=see_link\">",
"     \"Prediction of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MULTIPLE ABNORMAL MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, pregnancy complications such as preeclampsia, fetal growth restriction, preterm birth, fetal death, placental abnormalities, and possibly abruptio placenta and oligohydramnios are more common among women with abnormal maternal analyte concentrations. This risk increases as the number of abnormal first",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    second trimester markers increases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/38,62,63\">",
"     38,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER) trial calculated the risk of adverse pregnancy outcome (eg, preterm birth, preeclampsia, pregnancy loss) based on the number of abnormal markers in the second trimester quad screen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/38\">",
"     38",
"    </a>",
"    ]. Women with two or more abnormal markers and specific combinations of abnormal markers were more likely to have an adverse pregnancy outcome than women with no or one abnormal marker. However, the associations were weak: the positive predictive value for various adverse pregnancies outcomes ranged from 1 to 18 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the efficacy of interventions for managing women found to have abnormal analyte levels in the first or second trimester and there is no consensus among experts as to how these pregnancies should be managed.",
"   </p>",
"   <p>",
"    In the United States, the Society for Maternal-Fetal Medicine (SMFM) published guidelines in 2010 for managing pregnancies of women with abnormal serum markers and no evidence of fetal aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/33\">",
"     33",
"    </a>",
"    ]. These guidelines provided thresholds for considering individual markers abnormal and suggestions about how to counsel patients and follow-up. No strong recommendations were made for specific interventions (eg, antenatal fetal testing).",
"   </p>",
"   <p>",
"    The Society of Obstetricians and Gynaecologists of Canada Genetics Committee recommends that obstetricians establish a care plan that takes into account the risks specific to individual patients. This plan may include enhanced patient education (eg, signs and symptoms of preterm labor and preeclampsia, recognition of decreased fetal movement), ultrasonography to assess fetal growth and amniotic fluid volume or cervical length, second trimester uterine artery Doppler examination to detect uteroplacental vasculopathy, and fetal surveillance (eg, biophysical profile, umbilical artery Doppler) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is no evidence that heightened pregnancy surveillance for preeclampsia, intrauterine growth restriction, preterm labor, or fetal demise improves the pregnancy outcome of these women. Further investigation is needed to determine whether any type of monitoring and intervention protocol would improve pregnancy outcome and be cost effective when abnormal markers are detected. We suggest that antenatal monitoring of pregnancies with abnormal analyte levels not be altered based upon screening results alone since heightened pregnancy surveillance of these women has not been proven to achieve earlier or improved detection of complications or improve pregnancy outcome compared to routine management of such pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18329/abstract/22,64\">",
"     22,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abnormal maternal analyte level noted during Down syndrome screening can be a marker for other chromosomal disorders and anomalies in the fetus and pregnancy complications (preeclampsia, fetal growth restriction, preterm birth, fetal death, placenta accreta) (",
"      <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66599 graphicRef54068 \" href=\"UTD.htm?35/2/35885\">",
"       table 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likelihood of an adverse outcome increases as the number of abnormal markers and the deviation from normal levels increase. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Multiple abnormal markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with adverse pregnancy outcomes do not have abnormal analyte levels (low sensitivity) and very few patients with abnormal analyte levels go on to have an adverse outcome (low positive predictive value). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'First trimester markers and adverse outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Second trimester markers and adverse outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that prenatal surveillance of pregnancies with abnormal analyte levels not be altered based upon screening results alone because of poor sensitivity and the fact that pregnancy surveillance of these women does not improve pregnancy outcome. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An exception is a very low unconjugated estriol level, which is associated with fetal steroid sulfatase deficiency and Smith-Lemli-Opitz syndrome. Further evaluation of these pregnancies will help identify these fetal disorders with high efficiency. We suggest these patients receive a detailed fetal ultrasound examination and referral to a genetic counselor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Low unconjugated estriol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     ACOG Committee Opinion: Committee on Obstetric Practice: Down syndrome screening: 1994; No. 141 (Replaces No. 76, 1989).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/2\">",
"      Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/3\">",
"      Palomaki GE, Lambert-Messerlian GM, Canick JA. A summary analysis of Down syndrome markers in the late first trimester. Adv Clin Chem 2007; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/4\">",
"      Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/5\">",
"      Tul N, Spencer K, Noble P, et al. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999; 19:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/6\">",
"      Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 2002; 22:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/7\">",
"      Breathnach FM, Malone FD, Lambert-Messerlian G, et al. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol 2007; 110:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/8\">",
"      Spencer K, Liao AW, Ong CY, et al. Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks. Prenat Diagn 2001; 21:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/9\">",
"      Kagan KO, Wright D, Maiz N, et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 32:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/10\">",
"      Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008; 23:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/11\">",
"      Kagan KO, Anderson JM, Anwandter G, et al. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation. Prenat Diagn 2008; 28:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/12\">",
"      Palomaki GE, Haddow JE, Knight GJ, et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 1995; 15:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/13\">",
"      Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996; 334:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/14\">",
"      Lambert-Messerlian GM, Saller DN Jr, Tumber MB, et al. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998; 18:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/15\">",
"      Bahado-Singh RO, Choi SJ, Oz U, et al. Early second-trimester individualized estimation of trisomy 18 risk by ultrasound. Obstet Gynecol 2003; 101:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/16\">",
"      Saller DN Jr, Canick JA, Blitzer MG, et al. Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999; 19:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/17\">",
"      Lehman CD, Nyberg DA, Winter TC 3rd, et al. Trisomy 13 syndrome: prenatal US findings in a review of 33 cases. Radiology 1995; 194:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/18\">",
"      Saller DN Jr, Canick JA, Schwartz S, Blitzer MG. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol 1992; 167:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/19\">",
"      Laundon CH, Spencer K, Macri JN, et al. Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies. Prenat Diagn 1996; 16:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/20\">",
"      Benn PA, Gainey A, Ingardia CJ, et al. Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn 2001; 21:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/21\">",
"      Oyer CE, Canick JA. Maternal serum hCG levels in triploidy: variability and need to consider molar tissue. Prenat Diagn 1992; 12:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/22\">",
"      Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/23\">",
"      Spencer K, Cowans NJ, Avgidou K, et al. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008; 31:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/24\">",
"      Spencer K, Cowans NJ, Molina F, et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 2008; 31:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/25\">",
"      Spencer K, Cowans NJ, Avgidou K, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006; 28:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/26\">",
"      Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/27\">",
"      Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/28\">",
"      Goetzl L, Krantz D, Simpson JL, et al. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004; 104:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/29\">",
"      Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/30\">",
"      Smith GC, Crossley JA, Aitken DA, et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004; 292:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/31\">",
"      Goetzinger KR, Cahill AG, Macones GA, Odibo AO. Association of first-trimester low PAPP-A levels with preterm birth. Prenat Diagn 2010; 30:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/32\">",
"      Spencer K, Yu CK, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005; 25:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/33\">",
"      Dugoff L, Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010; 115:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/34\">",
"      Krause TG, Christens P, Wohlfahrt J, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome(1). Obstet Gynecol 2001; 97:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/35\">",
"      Baschat AA, Harman CR, Farid G, et al. Very low second-trimester maternal serum alpha-fetoprotein: Association with high birth weight. Obstet Gynecol 2002; 99:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/36\">",
"      Palomaki GE, Hill LE, Knight GJ, et al. Second-trimester maternal serum alpha-fetoprotein levels in pregnancies associated with gastroschisis and omphalocele. Obstet Gynecol 1988; 71:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/37\">",
"      Schoen E, Norem C, O'Keefe J, et al. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other fetal conditions. Obstet Gynecol 2003; 102:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/38\">",
"      Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005; 106:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/39\">",
"      Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998; 91:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/40\">",
"      Craig WY, Palomaki G, Roberson M, Haddow JE. Further insights into implications of undetectable or very low unconjugated estriol in maternal serum during the second trimester. Prenat Diagn 2011; 31:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/41\">",
"      Langlois S, Armstrong L, Gall K, et al. Steroid sulfatase deficiency and contiguous gene deletion syndrome amongst pregnant patients with low serum unconjugated estriols. Prenat Diagn 2009; 29:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/42\">",
"      Bradley LA, Canick JA, Palomaki GE, Haddow JE. Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 1997; 176:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/43\">",
"      Brookes KJ, Hawi Z, Kirley A, et al. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/44\">",
"      Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 1994; 330:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/45\">",
"      Palomaki GE, Bradley LA, Knight GJ, et al. Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. J Med Screen 2002; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/46\">",
"      Bradley LA, Palomaki GE, Knight GJ, et al. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. Am J Med Genet 1999; 82:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/47\">",
"      Craig WY, Haddow JE, Palomaki GE, et al. Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. Prenat Diagn 2006; 26:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/48\">",
"      Craig WY, Haddow JE, Palomaki GE, Roberson M. Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz syndrome (SLOS). Prenat Diagn 2007; 27:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/49\">",
"      Kratz LE, Kelley RI. Prenatal diagnosis of the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet 1999; 82:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/50\">",
"      Nowaczyk MJ, Garcia DM, Eng B, Waye JS. Rapid molecular prenatal diagnosis of Smith-Lemli-Opitz syndrome. Am J Med Genet 2001; 102:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/51\">",
"      Bzd&uacute;ch V, Koz&aacute;k L, Francov&aacute; H, Beh&uacute;lov&aacute; D. Prenatal diagnosis of Smith-Lemli-Opitz syndrome by mutation analysis. Am J Med Genet 2000; 95:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/52\">",
"      Endres LK, Krotz S, Grobman WA. Isolated low second-trimester maternal serum beta-human chorionic gonadotropin is not associated with adverse pregnancy outcome. Am J Obstet Gynecol 2003; 189:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/53\">",
"      Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 2000; 20:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/54\">",
"      Chandra S, Scott H, Dodds L, et al. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003; 189:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/55\">",
"      Lepage N, Chitayat D, Kingdom J, Huang T. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 2003; 188:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/56\">",
"      Poon LC, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/57\">",
"      Cuckle H, Sehmi I, Jones R. Maternal serum inhibin A can predict pre-eclampsia. Br J Obstet Gynaecol 1998; 105:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/58\">",
"      Aquilina J, Barnett A, Thompson O, Harrington K. Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia. Am J Obstet Gynecol 1999; 181:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/59\">",
"      Lambert-Messerlian GM, Silver HM, Petraglia F, et al. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy. J Soc Gynecol Investig 2000; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/60\">",
"      Wald NJ, Morris JK. Multiple marker second trimester serum screening for pre-eclampsia. J Med Screen 2001; 8:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/61\">",
"      Kang JH, Farina A, Park JH, et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity. Prenat Diagn 2008; 28:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/62\">",
"      Chitayat D, Farrell SA, Huang T, et al. Double-positive maternal serum screening results for down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. Am J Obstet Gynecol 2002; 187:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/63\">",
"      Huang T, Hoffman B, Meschino W, et al. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn 2010; 30:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18329/abstract/64\">",
"      Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 2001; 184:1549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 419 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18329=[""].join("\n");
var outline_f17_57_18329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MARKERS USED FOR DOWN SYNDROME SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIRST TRIMESTER MARKERS AND OTHER FETAL ANEUPLOIDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trisomy 13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Triploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1318209\">",
"      Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SECOND TRIMESTER MARKERS AND OTHER FETAL ANEUPLOIDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Trisomy 13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Triploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FIRST TRIMESTER MARKERS AND ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Low pregnancy associated protein (PAPP)-A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Low beta-hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      High PAPP-A or high beta-hCG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SECOND TRIMESTER MARKERS AND ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Low alpha fetoprotein (AFP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      High AFP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318317\">",
"      - Placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318324\">",
"      - Fetal anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318331\">",
"      - Congenital nephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Low unconjugated estriol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318259\">",
"      - Placental sulfatase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318266\">",
"      - Smith-Lemli-Opitz syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      High unconjugated estriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Low or high hCG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MULTIPLE ABNORMAL MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/419|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/37/14942\" title=\"figure 1\">",
"      Smith-Lemli-Opitz syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/419|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/52/38732\" title=\"table 1\">",
"      Maternal serum marker pattern in selected fetal syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35355\" title=\"table 2\">",
"      Down syndrome screening terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/54/29548\" title=\"table 3A\">",
"      Maternal analyte changes associated w adverse pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/10/24748\" title=\"table 3B\">",
"      Single and combined maternal analyte changes and adverse outcome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=related_link\">",
"      Prediction of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34247?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal abdominal wall defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=related_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18330="Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)";
var content_f17_57_18330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/57/18330/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/57/18330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12145086\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic neuroendocrine tumors (pancreatic NETs), also known as islet cell tumors, are rare neoplasms that arise in the endocrine tissues of the pancreas (",
"    <a class=\"graphic graphic_picture graphicRef56960 \" href=\"UTD.htm?15/39/15988\">",
"     picture 1",
"    </a>",
"    ). They can secrete a variety of peptide hormones, including insulin, gastrin, glucagon, and vasoactive intestinal peptide (VIP), resulting in myriad clinical syndromes. In modern clinical series, however, up to 75 percent of pancreatic NETs are nonfunctioning (ie, unassociated with a hormonal syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    Pancreatic NETs represent approximately 3 percent of primary pancreatic neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/5\">",
"     5",
"    </a>",
"    ]. Their incidence has risen sharply in the United States over the past three decades, possibly due to increased detection of asymptomatic disease on cross-sectional imaging and endoscopy done for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145093\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;NETs arising at different sites within the body are classified according to their histologic features. While there are differences in terminology and grading for these tumors arising at different sites, all commonly used classification systems reflect a basic separation between more indolent, well differentiated tumors and far more aggressive poorly differentiated types that behave clinically more like small cell carcinoma of the lung.",
"   </p>",
"   <p>",
"    In keeping with this general philosophy, the World Health Organization (WHO) classifies NETs arising within the digestive system into two broad categories (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/7\">",
"     7",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H2474956#H2474956\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on '2010 WHO classification'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated neuroendocrine tumors, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. This category is further separated, according to proliferative rate, into low-grade (G1) and intermediate grade (G2) subgroups.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas are all high-grade (G3) tumors. Their clinical behavior that resembles small cell or large cell neuroendocrine carcinoma of the lung. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Well-differentiated NETs arising in the gastrointestinal tract have traditionally been referred to as carcinoid or pancreatic (islet cell) neuroendocrine tumors. Carcinoid tumors may arise from multiple organ systems, including the small bowel, appendix, rectum, stomach, and lungs. In contrast, pancreatic NETs arise from the pancreas and rarely within the wall of the duodenum. Although carcinoid tumors and pancreatic NETs may have similar characteristics on routine histologic evaluation, they have a different pathogenesis and biology, and response to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The nomenclature of pancreatic NETs has evolved considerably over the last two decades. The term &ldquo;pancreatic carcinoid&rdquo; is no longer widely used. Likewise, use of the term &ldquo;islet cell tumor&rdquo; (which denotes the presumed origination of pancreatic NETs in the Islets of Langerhans) has declined. In recent years, the term &ldquo;pancreatic neuroendocrine tumor&rdquo; or &ldquo;pancreatic NET&rdquo; has been adopted by most practitioners as well as by the American Joint Committee on Cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/8\">",
"     8",
"    </a>",
"    ] and the World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/7\">",
"     7",
"    </a>",
"    ]. As noted above, the term pancreatic neuroendocrine carcinoma is reserved for those cases with poorly differentiated histology and a high proliferative rate (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6984431\">",
"    <span class=\"h2\">",
"     Functionality and nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functionality also impacts on nomenclature. Pancreatic NETs that are functioning (hormone secreting) are classified according to the predominant hormone they secrete and the resulting clinical syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H799428#H799428\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Functionality and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An insulin-producing pancreatic NET causing episodic hypoglycemia is considered to be an insulinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"       \"Insulinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A gastrin-producing tumor associated with the Zollinger-Ellison syndrome is termed a gastrinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other functioning pancreatic NETs that secrete glucagon (glucagonomas), somatostatin (somatostatinomas), or vasoactive intestinal polypeptide (VIPomas) are quite rare, with an estimated annual incidence of approximately 1 in 10 million. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link\">",
"       \"Glucagonoma and the glucagonoma syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"       \"Somatostatinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, immunohistochemical staining is not a defining criterion for tumor classification. For example, if a tumor stains for gastrin but does not produce symptoms of the Zollinger-Ellison syndrome, it is not considered a gastrinoma.",
"   </p>",
"   <p>",
"    Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functioning pancreatic NETs is defined by the grade and stage of the tumor, as it is with nonfunctioning tumors. Thus, the pathologic diagnosis of a functioning pancreatic NET should be the same as for a nonfunctioning NET (ie, well-differentiated or poorly differentiated NET), with the descriptive functional designation appended to the diagnosis where there is knowledge of a clinical syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4808918\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic NETs have an incidence of approximately 1 per 100,000 individuals per year and account for 1 to 2 percent of all pancreatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although they may manifest at any age, they most often occur in the fourth to sixth decades of life.",
"   </p>",
"   <p>",
"    Most pancreatic NETs are sporadic, but they can be associated with hereditary endocrinopathies, including multiple endocrine neoplasia type I (MEN1), von Hippel Lindau (VHL) syndrome, neurofibromatosis type I (NF1), and tuberous sclerosis (",
"    <a class=\"graphic graphic_table graphicRef70019 \" href=\"UTD.htm?12/56/13196\">",
"     table 2",
"    </a>",
"    ). Approximately 80 to 100 percent of patients with MEN1, up to 20 percent of patients with VHL, 10 percent of patients with NF1, and 1 percent of patients with tuberous sclerosis will develop a pancreatic NET within their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Importantly, patients who develop a pancreatic NET in the context of an inherited syndrome must be considered separately with regard to prognosis, as these tumors tend to be associated with a more indolent course than do sporadic tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24623092\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pancreatic NETs has evolved in recent years. Up until two decades ago, most pancreatic NETs were described as functioning and detected following diagnostic evaluation of a hormonal syndrome. In contrast, more recent clinical series describe the majority (50 percent or more) of pancreatic NETs as nonfunctioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/2,12-17\">",
"     2,12-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7452147\">",
"    <span class=\"h2\">",
"     Functioning tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of functional tumors is addressed in detail elsewhere. In brief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulinomas typically present with episodic hypoglycemia, which may cause confusion, visual change, unusual behavior, palpitations, diaphoresis, and tremulousness. Amnesia for hypoglycemia is common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H6#H6\">",
"       \"Insulinoma\", section on 'Symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrinomas typically present with peptic ulcer disease; diarrhea can also be a prominent feature. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical syndrome classically associated with glucagonoma includes necrolytic migratory erythema, cheilitis, diabetes mellitus, anemia, weight loss, diarrhea, venous thrombosis, and neuropsychiatric symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link&amp;anchor=H4#H4\">",
"       \"Glucagonoma and the glucagonoma syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The main clinical features of the VIPoma syndrome are watery diarrhea, hypokalemia, and hypochlorhydria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link&amp;anchor=H3#H3\">",
"       \"The VIPoma syndrome\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7452214\">",
"    <span class=\"h2\">",
"     Nonfunctioning tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonfunctioning pancreatic NETs do secrete a number of substances such as chromogranins, neuron-specific enolase, pancreatic polypeptide, and ghrelin, they do not present clinically with a hormonal syndrome as compared to their functional counterparts. As a result, they often present later in the course of the disease with symptoms of local compression or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. However, mean tumor diameter has decreased in the last two decades, attributed to the increased use of cross-sectional imaging, and a larger percentage of tumors (40 and 50 percent of nonmetastatic PNETs in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]) are now detected incidentally in asymptomatic patients who undergo diagnostic evaluations for unrelated conditions.",
"   </p>",
"   <p>",
"    When symptomatic, the most common presenting symptoms of a nonfunctioning pancreatic NET are abdominal pain (35 to 78 percent), weight loss (20 to 35 percent), and anorexia and nausea (45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Less frequent signs include obstructive jaundice (17 to 50 percent), intraabdominal hemorrhage (4 to 20 percent), or a palpable mass (7 to 40 percent). Symptoms may also be attributable to metastatic disease. In a variety of published reports, between 32 and 73 percent of cases are metastatic at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/6,12,26-28\">",
"     6,12,26-28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145100\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES FOR DISEASE LOCALIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4809019\">",
"    <span class=\"h2\">",
"     Overview of the diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to a patient with a suspected pancreatic NET depends on the clinical scenario:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a biopsy-proven pancreatic NET require appropriate radiographic staging studies in order to determine the extent of disease spread in order to plan appropriate treatment. In some cases, a patient may present with confirmed metastatic disease (most often in the liver; other less common sites include retroperitoneal lymph nodes and bone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/29\">",
"       29",
"      </a>",
"      ]), and the diagnostic approach focuses on identifying both the extent of disease spread and the likely primary site of disease. In patients with either metastatic or nonmetastatic disease, cross-sectional imaging studies such as multiphasic CT scan or magnetic resonance imaging (MRI) are indicated. Imaging should focus on the abdomen; the value of chest imaging is questionable. Somatostatin-receptor scintigraphy (SRS, OctreoScan) is recommended in guidelines from the European Neuroendocrine Tumor Society [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/30\">",
"       30",
"      </a>",
"      ], the British Society of Gastroenterology [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/31\">",
"       31",
"      </a>",
"      ], and the European Society for Medical Oncology (ESMO) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/32\">",
"       32",
"      </a>",
"      ]; the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      suggests its use &ldquo;if appropriate&rdquo;. However, the importance of SRS has been questioned by others [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occasionally, patients present with a hormonal syndrome suggestive of a pancreatic NET (such as hypoglycemia with confirmed hyperinsulinemia on a monitored fast), but lack evidence of disease on conventional imaging. These patients may require highly specialized localizing evaluations that may include endoscopic ultrasonography or arterial stimulation with venous sampling (ASVS). The combined use of conventional imaging and endoscopic studies for an occult hormonally-functioning pancreatic NET (such as a subcentimeter insulinoma) has improved the sensitivity of preoperative detection to nearly 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H13#H13\">",
"       \"Insulinoma\", section on 'Tumor localization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will review the data on the utility of the available imaging techniques in patients with pancreatic NETs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145107\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans are noninvasive and readily available. Helical (spiral) multiphasic contrast-enhanced CT is recommended for evaluation of patients with pancreatic NETs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link&amp;anchor=H3#H3\">",
"     \"Computed tomography of the hepatobiliary tract\", section on 'Contrast material'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link&amp;anchor=H5#H5\">",
"     \"Computed tomography of the hepatobiliary tract\", section on 'Helical (spiral) CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most NETs are highly vascular, and liver metastases may appear isodense with the liver on a noncontrasted study. Following the injection of intravenous (IV) contrast, pancreatic NETs often enhance with iodinated contrast during the early arterial phase (approximately 20 seconds after contrast injection), with washout during the portal venous imaging phase (approximately 70 seconds after contrast injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared to the surrounding normal liver parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52935 \" href=\"UTD.htm?16/0/16392\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scans are highly accurate for detecting primary pancreatic NETs; using modern multiphase imaging techniques, sensitivity is &gt;80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Tumors as small as 4 mm have been visualized with CT scanning; however, sensitivity is decreased for tumors smaller than 2 cm in diameter compared to larger tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/37\">",
"     37",
"    </a>",
"    ]. Small tumors can often appear as rounded, enhancing vascular lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69231 \" href=\"UTD.htm?2/16/2307\">",
"     image 2",
"    </a>",
"    ); others may be hypodense or cystic (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62453 \" href=\"UTD.htm?27/40/28290\">",
"     image 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Symptomatic but nonfunctioning tumors, VIPomas, and glucagonomas are usually large (&gt;3 cm) at the time of diagnosis. The sensitivity of contrast-enhanced CT for these tumors approaches 100 percent, and it is considered the imaging study of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145114\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;On MRI, pancreatic NETs are typically characterized by low signal intensity on T1-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59487 \" href=\"UTD.htm?10/32/10754\">",
"     image 4",
"    </a>",
"    ), and high signal intensity on T2-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72303 \" href=\"UTD.htm?17/15/17654\">",
"     image 5",
"    </a>",
"    ). Early series examining the role of MRI for the detection of NETs were disappointing. However, with the advent of newer techniques, such as short tau inversion recovery (STIR) sequences, sensitivity has improved substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 28 consecutive patients with a clinically suspected functioning pancreatic NET, MRI detected a pancreatic NET in 17 of 20 patients in whom it was done (sensitivity 85 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/41\">",
"       41",
"      </a>",
"      ]. Specificity was 100 percent, and the positive and negative predictive values were 100 and 73 percent, respectively. In this study, the gold standard for diagnosis of a pancreatic NET was either resection (n= 19) or clinical followup for at least a year.",
"     </li>",
"     <li>",
"      In another study of 64 patients with metastatic NETs, multiphasic MRI detected more hepatic lesions than either contrast-enhanced CT or somatostatin receptor scintigraphy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/44\">",
"       44",
"      </a>",
"      ]. As a result of this greater sensitivity for liver metastases, some physicians prefer MRI over CT for assessing the status of the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/43\">",
"       43",
"      </a>",
"      ]. This subject is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with CT scans, early arterial phase imaging following the injection of gadolinium contrast is critical for the detection of small hypervascular liver metastases. In a study of 37 patients with liver metastases from gastroenteropancreatic NETs, the most sensitive sequences for detection of liver metastases were hepatic arterial phase and fast spin-echo T2-weighed images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72303 \" href=\"UTD.htm?17/15/17654\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145121\">",
"    <span class=\"h2\">",
"     Endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasonography (EUS) provides high-resolution imaging of the pancreas, and it can detect lesions as small as 2 to 3 mm in diameter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74947 \" href=\"UTD.htm?13/61/14288\">",
"     image 6",
"    </a>",
"    ). Studies of EUS for detecting pancreatic NETs suggest high sensitivity for tumor detection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/34,37,42,43,45-48\">",
"     34,37,42,43,45-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 37 patients who had negative imaging workup with transabdominal ultrasonography and CT scan and were later shown to have a pancreatic NET, EUS detected the tumor with high sensitivity (82 percent) and specificity (95 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 56 patients, EUS had a higher sensitivity than helical, contrast-enhanced CT scan (92 versus 63 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/37\">",
"       37",
"      </a>",
"      ]. Of the 22 tumors missed on CT, 20 were detected on EUS.",
"     </li>",
"     <li>",
"      In another report, EUS was more sensitive than either CT or transabdominal ultrasonography for detection and localization of pancreatic NETs in patients with multiple endocrine neoplasia type 1 (MEN-1) syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/48\">",
"       48",
"      </a>",
"      ]. In this report, sensitivity for tumors less than 6 mm in diameter was poor as determined by inspection of resected specimens by pathologists. However, others suggest acceptable reproducibility for EUS in detecting small pancreatic NETs in patients with MEN-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/49\">",
"       49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although routine screening of asymptomatic patients with MEN-1 with EUS has been recommended, this is a controversial area and the optimal screening strategy in these patients remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H10#H10\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Nonfunctioning pancreatic tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      EUS has also proven to be a useful tool for identifying pancreatic NETs such as gastrinomas that arise in the duodenal wall and have a high frequency of metastases to the peripancreatic lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/50\">",
"       50",
"      </a>",
"      ]. Duodenal gastrinomas are notoriously difficult to localize by CT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another benefit of EUS is that EUS-guided fine-needle aspiration biopsy can often provide a non-operative histologic diagnosis of pancreatic NET [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS is limited by the requirement of a highly skilled endoscopist and by its inability to consistently visualize the pancreatic tail. Nevertheless, this technique has proven useful for the localization of primary pancreatic NETs in patients without metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145128\">",
"    <span class=\"h2\">",
"     Somatostatin-receptor scintigraphy (OctreoScan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pancreatic NETs express high levels of somatostatin receptors and can therefore be imaged with a radiolabeled form of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (111-indium pentetreotide, OctreoScan) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85671 \" href=\"UTD.htm?34/41/35472\">",
"     image 7",
"    </a>",
"    ). Somatostatin receptor scintigraphy (SRS) has proven particularly effective for visualizing gastrinomas, glucagonomas, and nonfunctioning pancreatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. Because insulinomas, the most frequent type of functioning pancreatic NET, express relatively scant levels of subtype 2 somatostatin receptors, they are less likely to be detected on SRS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Poorly differentiated neuroendocrine tumors (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) also express low somatostatin receptor levels and are unlikely to be detected on SRS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H9#H9\">",
"     \"Insulinoma\", section on 'Diagnosis and staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H13#H13\">",
"     \"Insulinoma\", section on 'Tumor localization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SRS has the additional advantage of instantaneous whole body scanning, which also allows detection of metastases outside of the abdominal region.",
"   </p>",
"   <p>",
"    The accuracy of SRS has improved with the addition of single photon emission computed tomography (SPECT) to planar imaging, since SPECT permits more accurate differentiation between areas of pathologic and physiologic uptake in the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In a report describing 72 patients with gastroenteropancreatic NETs (ie, carcinoid, pancreatic NET, or other neuroendocrine tumor) who were examined with",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    hybrid imaging, localization was improved in 23 of 44 SRS positive studies, and the test affected clinical management in 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older studies, the sensitivity of SRS compared favorably with other imaging modalities. In one series, for example, SRS detected primary gastrinomas at a rate of 58 percent, a sensitivity equal to that of other imaging studies (ultrasonography, CT, MRI, and angiography) combined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/42\">",
"     42",
"    </a>",
"    ]. In another, SRS was superior to CT scanning for localizing gastrinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, technological advancements in CT and MRI and EUS over the past several decades have led some to question whether SRS is still a necessary component of the staging workup for gastroenteropancreatic NETs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 121 patients with a gastroenteropancreatic NET, 107 of whom had metastatic disease, multiphase contrast-enhanced CT or MRI detected more pathologic lesions than did SPECT-SRS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/33\">",
"       33",
"      </a>",
"      ]. Of the 107 patients with metastatic disease that was demonstrated by CT or MRI, only 85 (79 percent) had abnormal findings on SRS that correlated with the abnormalities on cross-sectional imaging. Furthermore, none of the 107 patients had soft tissue abnormalities or primary tumors identified by SPECT-SRS that were not also seen on cross-sectional imaging. SPECT-SRS did identify clinically unsuspected bone metastases that were not identified on CT or MRI.",
"      <br/>",
"      <br/>",
"      The authors concluded that the routine use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      scanning as an adjunct for tumor staging was not justified unless the finding of asymptomatic bone lesions would change patient management and the treatment plan.",
"     </li>",
"     <li>",
"      Another study included 145 patients who underwent both SRS and cross sectional imaging with",
"      <span class=\"nowrap\">",
"       CT/MRI",
"      </span>",
"      for initial tumor evaluation or metastatic surveillance of disease at a single institution over a seven-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/63\">",
"       63",
"      </a>",
"      ]. Among the 37 evaluated for the presence of a new tumor, 20 had biochemical evidence of a NET and cross-sectional imaging was substantially superior to SRS, detecting 12 versus 3 primary tumors (60 versus 15 percent). Among the 54 cases with suspected recurrent NET and biochemical evidence for disease recurrence, cross sectional imaging was also superior, detecting tumors in 33 versus 17 cases (61 versus 31 percent). SRS identified disease foci not seen on cross-sectional imaging in just 8 of 74 patients with biochemical evidence of disease, and only altered surgical management in three. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in our view, there is still a place for SRS in the evaluation of a patient with a pancreatic NET. In addition to anatomical information, SRS offers functional information on levels of somatostatin-receptor expression; this can help in the selection of appropriate candidates with advanced disease for somatostatin-based therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In centers that perform peptide receptor radioligand therapy with radiolabeled somatostatin analogs such as 90-Y-DOTA tyr3-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (",
"      <sup>",
"       90",
"      </sup>",
"      Y-edotreotide) or 177-Lu-DOTA, Tyr",
"      <sup>",
"       3",
"      </sup>",
"      -octreotate (177-Lu-DOTATOC), SRS is an essential component of workup since levels of radiotracer uptake predict response to treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949126#H190949126\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Radiolabeled somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is less clear whether the level of radiotracer uptake predicts response to the conventional, non-radiolabeled somatostatin analogs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"       lanreotide",
"      </a>",
"      . Some physicians advocate baseline SRS prior to treatment with a somatostatin analog; however, patients with hormonal syndromes and a negative SRS may respond to therapy with a somatostatin receptor analog. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145135\">",
"    <span class=\"h2\">",
"     Arterial stimulation venous sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cases in which radiographically occult, hormonally functional tumors elude detection by conventional imaging modalities, invasive approaches may be necessary to localize tumors to a particular region of the pancreas for treatment planning purposes (eg, tail,",
"    <span class=\"nowrap\">",
"     body/neck,",
"    </span>",
"    <span class=\"nowrap\">",
"     head/uncinate).",
"    </span>",
"   </p>",
"   <p>",
"    Transhepatic portal venous sampling (THPVS) is a technically demanding technique in which small peripancreatic veins are accessed and tested for levels of hormones such as insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/45\">",
"     45",
"    </a>",
"    ]. A more recent innovation, arterial stimulation with hepatic venous sampling (ASVS), involves selective injection of a stimulating secretagogue (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    for gastrinomas and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    for insulinomas) into arteries supplying the pancreas with subsequent sampling of the hepatic venous effluent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/39,64-66\">",
"     39,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective comparison of this technique with portal venous sampling in patients with gastrinomas revealed it to have a higher sensitivity (89 percent) and fewer complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/64\">",
"     64",
"    </a>",
"    ]. Results with insulinomas are also encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. One report evaluated 24 patients with proven hyperinsulinemia, seven of whom had negative radiologic workups (ultrasonography, CT, MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/66\">",
"     66",
"    </a>",
"    ]. At surgery, six had an insulinoma and one had nodular hyperplasia. In all seven patients, infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    permitted localization of the source of insulin secretion.",
"   </p>",
"   <p>",
"    While techniques such as THPVS and ASVS are valuable for patients with radiographically occult hormonally functioning tumors, the need for them has diminished due to improved sensitivity of other imaging modalities including CT, MRI, and EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145142\">",
"    <span class=\"h2\">",
"     Intraoperative localization techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative ultrasonography allows high resolution examination of the pancreas. When combined with palpation of the organ, the sensitivity for tumor detection ranges from 83 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/39,68,69\">",
"     39,68,69",
"    </a>",
"    ]. Intraoperative transillumination has equivalent efficacy (sensitivity of 83 percent) for the localization of duodenal wall gastrinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither of these tests should replace preoperative imaging; they are used as adjuncts to intraoperative palpation in patients who still have a suspected hormone-secreting pancreatic NET that cannot be identified or localized preoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145149\">",
"    <span class=\"h2\">",
"     Functional PET imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not yet widely available, several positron emission tomography (PET) tracers for functional imaging have emerged (18-F-dihydroxy-phenyl-alanine [18F-DOPA], 11-C-5-hydroxytryptophan [11-C-5-HTP]), and 68-Ga-DOTA- D-Phe",
"    <sup>",
"     1",
"    </sup>",
"    -Tyr",
"    <sup>",
"     3",
"    </sup>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    (68-Ga-DOTATOC), which, in combination with high resolution PET integrated with CT, hold promise for improved detection and staging of NETs in the future. These novel PET modalities offer higher spatial resolution than conventional somatostatin receptor scintigraphy (SRS) and are associated with improved sensitivity for detection of small lesions. This subject is discussed in detail elsewhere.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H7#H7\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Other functional imaging methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24623272\">",
"    <span class=\"h2\">",
"     Laboratory diagnostics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of peptide markers may be used to aid in the diagnoses and posttreatment follow-up patients with pancreatic NETs, some of which are specific to the tumor site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24623280\">",
"    <span class=\"h3\">",
"     Nonfunctioning tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonfunctioning pancreatic NETs are not associated with a clinical hormonal syndrome, they may secrete proteins that can be measured in serum. Chromogranin A (CgA) is the most commonly secreted and measured tumor marker associated with all types of gastroenteropancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Levels are elevated in approximately 70 percent of patients with nonfunctioning (and functioning) pancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CgA expression generally correlates with dense-core secretory vesicle number in neuroendocrine cells. Plasma levels of CgA are thought to correlate with tumor burden, and the overall diagnostic sensitivity is higher in patients with metastatic disease (60 to 100 percent) than in patients with localized disease (29 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/70,75-77\">",
"     70,75-77",
"    </a>",
"    ], although this has not been seen in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/74\">",
"     74",
"    </a>",
"    ]. False positive elevations of CgA can be present in a number of other conditions (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 3",
"    </a>",
"    ). They are especially common in patients who are taking a proton pump inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromogranins B and C are less sensitive indicators of gastroenteropancreatic NETs compared to CgA, and they are not used clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic polypeptide is another nonspecific biochemical marker for nonfunctioning pancreatic NETs, but it has a relatively low sensitivity when used alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/74,81\">",
"     74,81",
"    </a>",
"    ]. In one study, sensitivity for pancreatic NETS (the majority of which were nonfunctioning) was 63 percent, and specificity was 81 percent compared to normal disease-free controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/74\">",
"     74",
"    </a>",
"    ]. Compared to CgA alone, the combined use of pancreatic polypeptide plus CgA improved sensitivity for nonfunctioning pancreatic NETs from 68 to 93 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24623346\">",
"    <span class=\"h3\">",
"     Functioning tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functioning pancreatic NETs also secrete CgA, and levels of this marker are elevated in approximately 75 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/70,74\">",
"     70,74",
"    </a>",
"    ]. However, for functioning PNETs, the levels of the secreted hormone represent a specific tumor marker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucagonoma and the glucagonoma syndrome\", section on 'Serum glucagon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"     \"Somatostatinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26599949\">",
"    <span class=\"h1\">",
"     STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two staging systems are available for pancreatic NETs, one from the American Joint Committee on Cancer (AJCC, which covers both pancreatic exocrine and neuroendocrine malignancies (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 4",
"    </a>",
"    )), and another proposed by the European Neuroendocrine Tumor Society (ENETS) (",
"    <a class=\"graphic graphic_table graphicRef86409 \" href=\"UTD.htm?13/2/13357\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/82\">",
"     82",
"    </a>",
"    ]. Both staging systems are highly prognostic for both relapse-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report comparing both staging systems in 94 patients with initially nonmetastatic, surgically resected pancreatic NET, the five-year RFS rates for stages I, II, and III disease were 90, 73, and 66 percent using the AJCC system, and 100, 84, and 75 percent according to the ENETS classification [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a separate analysis of 425 patients with pancreatic NETs treated over an 11-year period at the same institution, the five-year overall survival rates using the ENETS classification for stages I, II, III and IV disease were 100, 88, 85, and 57 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/57/18330/abstract/84\">",
"       84",
"      </a>",
"      ]. The corresponding values using the AJCC classification were 92, 84, 81, and 57 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12145156\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern imaging modalities have led to significant improvements in the localization and accurate staging of pancreatic neuroendocrine tumors (NETs).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modern multiphasic, high-resolution cross-sectional imaging with CT and MRI is highly sensitive for identification of primary pancreatic NETs as well as liver metastases. Early arterial phase imaging is particularly valuable for detection of hypervascular primary tumors and liver metastases. (See",
"      <a class=\"local\" href=\"#H12145107\">",
"       'Computed tomography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12145114\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatostatin-receptor-scintigraphy (SRS, OctreoScan) offers whole-body imaging and functional information regarding tumoral expression of somatostatin receptors. However, its ability to detect subcentimeter tumors is relatively poor compared to CT and MRI scans, and sensitivity is low for the detection of insulinomas as well as poorly-differentiated or high-grade tumors. (See",
"      <a class=\"local\" href=\"#H12145128\">",
"       'Somatostatin-receptor scintigraphy (OctreoScan)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic ultrasonography (EUS) is highly sensitive for detection of occult, subcentimeter pancreatic NETs, and it plays an important role in the evaluation of patients with functional NETs that are undetectable using conventional imaging techniques. Through endoscopic fine-needle aspiration biopsy, EUS also offers the ability to obtain a non-operative histopathologic diagnosis. (See",
"      <a class=\"local\" href=\"#H12145121\">",
"       'Endoscopic ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients presenting with hormonal syndromes such as hypoglycemia or Zollinger-Ellison syndrome, the diagnostic modalities listed above (CT, MRI, SRS, EUS) can detect nearly 100 percent of pancreatic NETs. As a result, invasive localizing techniques (such as arterial stimulation with venous sampling) are rarely necessary in modern practice. (See",
"      <a class=\"local\" href=\"#H12145135\">",
"       'Arterial stimulation venous sampling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1615481\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to imaging patients with suspected or biopsy-proven pancreatic NETs is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with a biopsy-proven well-differentiated NET in the pancreas or liver, we recommend helical triple-phase CT (arterial phase, portal venous phase, noncontrast) or multiphasic contrast-enhanced MRI of the abdomen to stage the extent of disease. If the results would potentially change management or the treatment plan, we perform somatostatin receptor scintigraphy with SPECT imaging in order to assess for somatostatin-receptor expression and evaluate for extra-abdominal (predominantly bone) metastases.",
"     </li>",
"     <li>",
"      For patients who present with hormonal syndromes suspicious for a pancreatic NET but who lack evidence of disease on conventional cross-sectional imaging, we recommend endoscopic ultrasound (EUS). EUS with fine-needle aspiration can also be used to establish a pathologic diagnosis, particularly in patients with early-stage disease.",
"      <br/>",
"      <br/>",
"      In rare cases where there is strong clinical and biochemical evidence for an occult pancreatic NET that is undetectable on EUS, we perform arterial stimulation with portal venous sampling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1615474\">",
"    <span class=\"h2\">",
"     Laboratory diagnostics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromogranin A (CgA) is the most commonly secreted and measured hormone associated with all types of gastroenteropancreatic NETs. CgA or pancreatic polypeptide can be followed as tumor markers if elevated at baseline. False positive elevations of CgA are often seen in patients taking proton pump inhibitors. For patients with functioning pancreatic NETs, the levels of the secreted hormone represent a more specific tumor marker. (See",
"      <a class=\"local\" href=\"#H24623272\">",
"       'Laboratory diagnostics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Solcia E, Kloppel G, Sobin LH.. Histological typing on endocrine tumors. In: WHO International Classification of Tumors, 2nd, Springer, Berlin, Germany 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/2\">",
"      Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20:2633.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Classification of Tumours of the Digestive System., Bosman F, Carneiro F, Hruban R, Thiese N.  (Eds), IARC Press, Lyon, France 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/4\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/5\">",
"      Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/6\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/9\">",
"      Kl&ouml;ppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/10\">",
"      Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol 2007; 20 Suppl 1:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/11\">",
"      Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/12\">",
"      Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010; 105:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/13\">",
"      Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/14\">",
"      Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/15\">",
"      Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/16\">",
"      Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/17\">",
"      Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/18\">",
"      Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007; 142:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/19\">",
"      Li J, Luo G, Fu D, et al. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med Oncol 2011; 28:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/20\">",
"      Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 2009; 16:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/21\">",
"      Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol 2012; 19:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/22\">",
"      Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 1993; 80:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/23\">",
"      Madura JA, Cummings OW, Wiebke EA, et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997; 63:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/24\">",
"      Matthews BD, Heniford BT, Reardon PR, et al. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/25\">",
"      Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/26\">",
"      Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/27\">",
"      Pape UF, Jann H, M&uuml;ller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/28\">",
"      Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/29\">",
"      Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 2009; 38:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/30\">",
"      Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/31\">",
"      Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/32\">",
"      &Ouml;berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/33\">",
"      Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/34\">",
"      Nikfarjam M, Warshaw AL, Axelrod L, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008; 247:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/35\">",
"      Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/36\">",
"      Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/37\">",
"      Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/38\">",
"      Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/39\">",
"      King CM, Reznek RH, Dacie JE, Wass JA. Imaging islet cell tumours. Clin Radiol 1994; 49:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/40\">",
"      Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/41\">",
"      Thoeni RF, Mueller-Lisse UG, Chan R, et al. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/42\">",
"      Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/43\">",
"      Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/44\">",
"      Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/45\">",
"      Vinik AI, Delbridge L, Moattari R, et al. Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience. Surgery 1991; 109:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/46\">",
"      R&ouml;sch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/47\">",
"      Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/48\">",
"      Hellman P, Hennings J, Akerstr&ouml;m G, Skogseid B. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg 2005; 92:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/49\">",
"      Kann PH, Kann B, Fassbender WJ, et al. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006; 114:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/50\">",
"      Cadiot G, Lebtahi R, Sarda L, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996; 111:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/51\">",
"      Chatzipantelis P, Salla C, Konstantinou P, et al. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases. Cancer 2008; 114:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/52\">",
"      Atiq M, Bhutani MS, Bektas M, et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci 2012; 57:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/53\">",
"      Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/54\">",
"      Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/55\">",
"      Modlin IM, Cornelius E, Lawton GP. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995; 130:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/56\">",
"      Fj&auml;llskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/57\">",
"      Kimura N, Pilichowska M, Date F, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 1999; 5:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/58\">",
"      Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/59\">",
"      Zimmer T, St&ouml;lzel U, B&auml;der M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/60\">",
"      Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/61\">",
"      Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/62\">",
"      Schirmer WJ, Melvin WS, Rush RM, et al. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995; 118:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/63\">",
"      Shaverdian N, Pinchot SN, Zarebczan B, et al. Utility of &sup1;&sup1;&sup1;indium-pentetreotide scintigraphy in patients with neuroendocrine tumors. Ann Surg Oncol 2013; 20:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/64\">",
"      Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/65\">",
"      Doppman JL, Miller DL, Chang R, et al. Insulinomas: localization with selective intraarterial injection of calcium. Radiology 1991; 178:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/66\">",
"      Pereira PL, Roche AJ, Maier GW, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology 1998; 206:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/67\">",
"      Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol 2008; 14:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/68\">",
"      Frucht H, Norton JA, London JF, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. Gastroenterology 1990; 99:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/69\">",
"      Huai JC, Zhang W, Niu HO, et al. Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. Am J Surg 1998; 175:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/70\">",
"      Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/71\">",
"      Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003; 148:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/72\">",
"      O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/73\">",
"      O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/74\">",
"      Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004; 27:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/75\">",
"      Nikou GC, Marinou K, Thomakos P, et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008; 8:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/76\">",
"      Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/77\">",
"      Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/78\">",
"      Pregun I, Hersz&eacute;nyi L, Juh&aacute;sz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/79\">",
"      Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/80\">",
"      Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/81\">",
"      Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000; 62 Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/82\">",
"      Rindi G, Kl&ouml;ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/83\">",
"      Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/57/18330/abstract/84\">",
"      Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2612 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18330=[""].join("\n");
var outline_f17_57_18330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12145156\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12145086\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12145093\">",
"      CLASSIFICATION AND NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6984431\">",
"      Functionality and nomenclature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4808918\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24623092\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7452147\">",
"      Functioning tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7452214\">",
"      Nonfunctioning tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12145100\">",
"      IMAGING STUDIES FOR DISEASE LOCALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4809019\">",
"      Overview of the diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145107\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145114\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145121\">",
"      Endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145128\">",
"      Somatostatin-receptor scintigraphy (OctreoScan)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145135\">",
"      Arterial stimulation venous sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145142\">",
"      Intraoperative localization techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12145149\">",
"      Functional PET imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24623272\">",
"      Laboratory diagnostics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24623280\">",
"      - Nonfunctioning tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24623346\">",
"      - Functioning tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26599949\">",
"      STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12145156\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1615481\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1615474\">",
"      Laboratory diagnostics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2612|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/0/16392\" title=\"diagnostic image 1\">",
"      CT neuroendocrine tumor liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/16/2307\" title=\"diagnostic image 2\">",
"      Subcentimeter enhancing pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/40/28290\" title=\"diagnostic image 3\">",
"      Cystic pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/32/10754\" title=\"diagnostic image 4\">",
"      MRI pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/15/17654\" title=\"diagnostic image 5\">",
"      T2 MRI well differentiated pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/61/14288\" title=\"diagnostic image 6\">",
"      EUS insulinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/41/35472\" title=\"diagnostic image 7\">",
"      CT-OctreoScan panc NET and liver mets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2612|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/39/15988\" title=\"picture 1\">",
"      Islet cell tumor Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17644\" title=\"table 1\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13196\" title=\"table 2\">",
"      Inherited disorders associated with pancreatic NETs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 3\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 4\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/2/13357\" title=\"table 5\">",
"      ENETS staging system for pancreatic NETS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=related_link\">",
"      Computed tomography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_57_18331="Criteria histrionic personality";
var content_f17_57_18331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for histrionic personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Is uncomfortable in situations in which he or she is not the center of attention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Interaction with others is often characterized by inappropriate sexually seductive or provocative behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Displays rapidly shifting and shallow expression of emotion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Consistently uses physical appearance to draw attention to self",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Style of speech that is excessively impressionistic and lacking in detail",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Shows self-dramatization, theatricality, and exaggerated expression of emotion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Is suggestible, ie, easily influenced by others or circumstances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Considers relationships to be more intimate than they actually are",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18331=[""].join("\n");
var outline_f17_57_18331=null;
var title_f17_57_18332="Fabrics decrease dust mites";
var content_f17_57_18332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fabrics for covering pillows and mattresses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"       Fabric permeability to allergens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Air flow through fabric",
"      </td>",
"      <td class=\"subtitle2\">",
"       Mite",
"      </td>",
"      <td class=\"subtitle2\">",
"       Cat",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plastic or vinyl covers",
"      </td>",
"      <td>",
"       Unmeasurable",
"      </td>",
"      <td>",
"       &lt;1.0 ng",
"      </td>",
"      <td>",
"       &lt;1.0 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Semipermeable fabrics*",
"      </td>",
"      <td>",
"       &lt;0.1 L/min",
"      </td>",
"      <td>",
"       &lt;1.0 ng",
"      </td>",
"      <td>",
"       &lt;1.0 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Unwoven synthetics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Type 1 (Filtrete)",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.3 L/min",
"      </td>",
"      <td class=\"sublist_other\">",
"       &lt;2.0 ng",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.3 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Type 2 (Propore)",
"      </td>",
"      <td class=\"sublist_other\">",
"       18 L/min",
"      </td>",
"      <td class=\"sublist_other\">",
"       &lt;2.0 ng",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.5 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Finely woven fabrics&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2 &micro;m",
"      </td>",
"      <td class=\"sublist_other\">",
"       8 L/min",
"      </td>",
"      <td class=\"sublist_other\">",
"       &lt;1 ng",
"      </td>",
"      <td class=\"sublist_other\">",
"       2 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       6.6 &micro;m",
"      </td>",
"      <td class=\"sublist_other\">",
"       16 L/min",
"      </td>",
"      <td class=\"sublist_other\">",
"       &lt;2 ng",
"      </td>",
"      <td class=\"sublist_other\">",
"       5.7 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       10 &micro;m",
"      </td>",
"      <td class=\"sublist_other\">",
"       19 L/min",
"      </td>",
"      <td class=\"sublist_other\">",
"       &lt;2 ng",
"      </td>",
"      <td class=\"sublist_other\">",
"       78 ng",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Traditional cotton or synthetic covers",
"      </td>",
"      <td>",
"       22 L/min",
"      </td>",
"      <td>",
"       133 ng",
"      </td>",
"      <td>",
"       580 ng",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Eg, Gortex and other porous materials.",
"    </div>",
"    <div class=\"reference\">",
"     &bull; From Vaughan, JW, et al, J Allergy Clin Immunol 1999; 103:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18332=[""].join("\n");
var outline_f17_57_18332=null;
var title_f17_57_18333="Specific cough child";
var content_f17_57_18333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to a child with chronic specific cough*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Underlying causes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        <p>",
"         Bronchospasm",
"        </p>",
"        <p>",
"         Environmental triggers",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Spirometry",
"        </p>",
"        <p>",
"         Chest radiography",
"        </p>",
"        <p>",
"         Allergy testing",
"        </p>",
"        <p>",
"         Trial of anti-asthma medications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent bacterial bronchitis",
"       </td>",
"       <td>",
"        <p>",
"         H. influenza",
"        </p>",
"        <p>",
"         S. pneumoniae",
"        </p>",
"        <p>",
"         M. catarrhalis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Empiric treatment with antibiotics (2 week course or more)",
"        </p>",
"        <p>",
"         Bronchoscopy with cultures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic suppurative lung disase/bronchiectasis, or recurrent pneumonia",
"       </td>",
"       <td>",
"        <p>",
"         Cystic fibrosis",
"        </p>",
"        <p>",
"         Ciliary dyskinesia",
"        </p>",
"        <p>",
"         Previous severe pneumonia",
"        </p>",
"        <p>",
"         Immunodeficiency",
"        </p>",
"        <p>",
"         Structural airway lesions",
"        </p>",
"        <p>",
"         Congenital lung lesions",
"        </p>",
"        <p>",
"         Missed foreign body",
"        </p>",
"        <p>",
"         TEF/H-fistula",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sweat test",
"        </p>",
"        <p>",
"         Bronchoscopy",
"        </p>",
"        <p>",
"         Cilia biopsy",
"        </p>",
"        <p>",
"         Immune workup",
"        </p>",
"        <p>",
"         HRCT chest",
"        </p>",
"        <p>",
"         Barium swallow",
"        </p>",
"        <p>",
"         Sputum cultures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration",
"       </td>",
"       <td>",
"        <p>",
"         Neurological abnormalities",
"        </p>",
"        <p>",
"         Weak cough reflex",
"        </p>",
"        <p>",
"         Neuromuscular disease",
"        </p>",
"        <p>",
"         Laryngeal abnormalities",
"        </p>",
"        <p>",
"         Adenotonsillar hypertrophy",
"        </p>",
"        <p>",
"         TEF/H-fistula",
"        </p>",
"        <p>",
"         Severe GERD",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Barium swallow",
"        </p>",
"        <p>",
"         Bronchoscopy and lavage",
"        </p>",
"        <p>",
"         Video fluoroscopy",
"        </p>",
"        <p>",
"         pH monitor",
"        </p>",
"        <p>",
"         Lung milk scan/salivagram",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic or less common infections",
"       </td>",
"       <td>",
"        <p>",
"         Tuberculosis",
"        </p>",
"        <p>",
"         Non-tuberculous mycobacteria",
"        </p>",
"        <p>",
"         Mycoses",
"        </p>",
"        <p>",
"         Parasites",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mantoux test",
"        </p>",
"        <p>",
"         Bronchoscopy and lavage",
"        </p>",
"        <p>",
"         HRCT chest",
"        </p>",
"        <p>",
"         Sputum cultures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial lung disease",
"       </td>",
"       <td>",
"        <p>",
"         Rheumatic diseases",
"        </p>",
"        <p>",
"         Cytotoxics",
"        </p>",
"        <p>",
"         Drugs",
"        </p>",
"        <p>",
"         External beam radiation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Autoimmune markers",
"        </p>",
"        <p>",
"         HRCT chest",
"        </p>",
"        <p>",
"         Lung biopsy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway abnormality",
"       </td>",
"       <td>",
"        <p>",
"         Tracheo-bronchomalacia",
"        </p>",
"        <p>",
"         Other intra-luminal lesions (eg, tumors)",
"        </p>",
"        <p>",
"         Extrinsic compressive lesions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bronhcoscopy and lavage",
"        </p>",
"        <p>",
"         CT chest",
"        </p>",
"        <p>",
"         MRI chest",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac",
"       </td>",
"       <td>",
"        <p>",
"         Pulmonary hypertension",
"        </p>",
"        <p>",
"         Cardiac edema",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pediatric cardiology consultation",
"        </p>",
"        <p>",
"         Echocardiogram",
"        </p>",
"        <p>",
"         Cardiac catheterization",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HRCT: high-resolution chest computerized tomography; TEF: tracheoesophageal fistula; GERD: gastroesophageal reflux disease; CT: computerized tomography; MRI: magnetic resonance imaging.",
"     <br>",
"      * \"Specific cough\" refers to a cough that is caused by an underlying abnormality or disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from guidelines in: Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1) Supplement: 260S-283S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18333=[""].join("\n");
var outline_f17_57_18333=null;
var title_f17_57_18334="Compliance with diet in HTN";
var content_f17_57_18334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Diminished compliance with nonpharmacologic antihypertensive therapy over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 212px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in weight, sodium intake (as estimated from urine sodium excretion), and exercise (measured by physical activity points) in patients with mild diastolic hypertension treated with combined dietary modification. Despite initial compliance, patients tended to return toward but not to baseline levels over a 48 month period. Although not shown, there was a persistent reduction in the number of alcoholic drinks from 3.6 to 2.5 drinks per week.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Neaton, JD, Grimm, RH Jr, Prineas, RJ, et al, JAMA 1993; 270:713.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18334=[""].join("\n");
var outline_f17_57_18334=null;
var title_f17_57_18335="Survival according to presence or absence of sleep ap PD pts";
var content_f17_57_18335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F87179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F87179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Estimate of survival according to absence or presence of significant sleep apnea among peritoneal dialysis patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a Kaplan-Meier estimate of survival among patients with and without significant sleep apnea (defined as Apnea-Hypopnea Index [AHI] &ge;15/hour or &lt;15/hour, respectively). P = 0.015.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Kidney International. Tang SC, Lam B, Yao TJ, et al. Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney Int 2010; 77:1031. Copyright &copy; 2010.",
"     <a href=\"file://www.nature.com/ki/index.html\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://www.nature.com/ki/index.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_57_18335=[""].join("\n");
var outline_f17_57_18335=null;
